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I don’t pretend we have all the answers.
But the questions
are certainly worth thinking about.
–Arthur C. Clarke
i
Abstract
Bone repair is not always a spontaneous process. In some cases, intervention is
required. This can involve the use of autograft but requires donor tissue. As a
consequence there is a potential lack of material and donor site morbidity. Current
alternatives are limited. There is a need for synthetic alternatives with a similar efficacy
to autograft. Growth factors are currently being explored to address this need. A
limiting factor to growth factor approaches are safety concerns and high costs. Both
these problems stem from the fact that growth factors have short in vivo half lives and
are administered at supraphysiological levels to maximise the duration of effect. There
is a strong need for a growth factor delivery system that canmaintain therapeutic doses
and restrict administration to a specific location. This is currently limited by the fragile
nature of growth factors.
Microparticles were utilised. Microparticles were formed from poly(DL-lactic-co-
glycolic acid) with a poly(ethylene glycol) based plasticiser. This provided a method
to modulate protein release based on the specific polymer formulation. Protein release
was assessed with a model protein. The biological activities of released growth factors
were assessed. Microparticles were fabricated for the delivery of vascular endothelial
growth factor (VEGF), platelet derived growth factor (PDGF) and bone morphogenetic
protein-2 (BMP-2) for release at time points conducive with osteogenic regeneration. A
method was developed and validated to combine these microparticles with a suitable
scaffold material. These composite scaffolds were developed with the intention of
assessing controlled release of growth factors in a bone segmental defect.
A method to fabricate microparticles with consistent size distributions and mor-
phologies was developed. Formulations were tailored such that protein release from
microparrticles could be from 2 days to 30 days. The biological activity of the released
model protein was verified, as was the biological activity of released BMP-2. A
method was devised to combine microparticles with a scaffold suitable for osteogenic
regeneration of a segmental defect. This composite scaffold maintained a high level of
porosity making it suitable for tissue ingress and growth factor diffusion.
ii
This study addresses key limitations to growth factor therapies. The sustained release
of growth factors has the potential to mitigate dose-induced toxic effects as well as
maintain therapeutic concentrations for longer periods. The nature of the delivery
systemdelivers localised growth factors minimising the risk of systemic dosing leading
to adverse reactions. This microparticle technology has potential in developmental
research research as well as clinical therapies.
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CHAPTER 1
Introduction
1.1 The Emergence of Tissue Engineering
"Tissue engineering is an interdisciplinary field that applies the principles
of engineering and the life sciences toward the development of biological
substitutes that restore, maintain, or improve tissue function." [1]
–Langer, 1993
Tissue engineering is a convergence of different disciplines. Tissue engineering draws
on the successes from clinical medicine, engineering and science. The current driving
force for developments in tissue engineering is a lack of transplants and a shortage of
efficacious implants for human organ or tissue replacements.
Tissue engineering has become synonymouswith regenerative medicine as the bound-
aries between replacement and repair become blurred.
1.2 Bone Physiology and Repair
1.2.1 Structure
Bone is a connective tissue with a number of important roles. Bone supports & protects
organs, transfers forces, produces red and white blood cells, stores minerals, stores
growth factors & fats and even has a role in sound transduction. Millions of years of
evolution have led to mechanisms that allows bone to accomplish these tasks.
Bone can be divided into two main categories based on structure: Cortical and
cancellous bone.
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1.2.1.1 Cortical Bone
Cortical bone, also known as compact or dense bone, makes up the hard outer layer
of bones. The porosity is relatively low, in the range 5–30 % [2]. Cortical bone is
responsible for around 80 % or the bone mass in an adult human.
1.2.1.2 Cancellous Bone
Cancellous bone, also known as trabecular or spongy bone, has a very open porous
network. This is essential since it contains blood vessels and bone marrow. Cancellous
bone is responsible for the remaining 20 % of bone mass in an adult human.
1.2.2 Fracture Repair and Remodelling
Bone remodelling is an ongoing and dynamic process. In the 19th century, Julius Wolff
proposed that bone is deposited or resorbed in accordance with the stresses placed
upon it. The results of this can be observed in weightlifters and astronauts [3]. This is
known as Wolff’s law.
1.2.2.1 Cell Types
Osteoblasts Osteoblasts are located on the surface of osteoid seams. They produce
a protein mixture, osteoid, which contains mainly type 1 collagen. This osteoid later
becomes mineralised so is the template for new bone development. Osteoblasts also
produce hormones thought to help regulate processes. Osteoblasts are immature bone
cells, once they become trapped within mineral they become osteocytes (bone cells).
Osteocytes Osteocytes are responsible for matrix maintenance. They help maintain
calcium homoeostasis, form new bone and act as mechano-sensory receptors.
Osteoclasts Osteoclasts are responsible for bone resorption. They are located on the
surface of bone in Howship’s lacunae (resorption pits).
1.2.2.2 Fracture Repair
Fracture repair is a proliferative physiological process and generally spontaneous.
Fracture healing consists of three main phases.
2
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1. Reactive phase.
2. Reparative Phase.
3. Remodelling phase.
This process is outlined in Figure 1.1.
Reactive Phase Blood cells accumulate in tissues adjacent to the injury site. This
forms a blood clot known as a hematoma. Within hours, cells within the hematoma
degenerate and die as well as some cells outside the clot. Firbroblasts survive within
this area and begin to replicate. This loose aggregation of cells develop small blood
vessels, this is known as granulation tissue. This provides structure and nutrients to
the site of repair.
Reparative Phase This phase begins days after fracture. Progenitor cells within the
periosteum, proliferate and differentiate. The periosteal progenitor cells proximal to
the fracture develop into chondroblasts and begin to form hyaline cartilage. Periosteal
cells distal to the fracture become osteoblasts and begin to produce woven bone.
As this is taking place, fibroblasts within the granulation tissue develop into chondrob-
lasts which also begin to form hyaline cartilage from within the granulation tissue.
Cartilagenous tissue continues to grow from each end of the fracture until it unites
forming a hetrogeneous tissue known as a soft callus. This callus provides sufficient
stability for blood vessels to begin to form.
Osteoblasts continue to lay down woven bone (which is quickly transformed into
lamellar bone) until the soft callus is transformed into bone. Once the cartilagenous
soft callus is completely transformed into a hard callus, fracture union is said to have
occurred.
Remodelling Phase During the normal bone healing process, more hard callus is
deposited than is needed. This results in a fracture that appears enlarged when viewed
under X-ray. Osteoblasts and osteoclasts deposit and remove bone and over a number
of years a normal shape is restored.
3
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Immediate Hours
Weeks Months
Figure 1.1: Schematic detailing the events during the course of a fracture repair. Very
soon after the fracture a hematoma forms. Over the course of days,
granulation tissue forms (reactive phase). From days to weeks woven bone
begins to appear (reparative phase). The new bone is remodelled over
months to years (remodelling phase). Original figure.
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1.2.3 Fracture Repair Complications
Complications are generally in the form of delayed-union or non-union fractures.
These conditions occur in 5–10 % of long bone fractures [4]. A delayed union fracture
can be defined as when a fracture shows clinical or radiological signs of healing but
fails to unite within an anticipated period of time [5]. A non-union fracture is defined
as when the normal biological healing process has stopped without union occurring.
Non-union fractures can be divided into atrophic and hypertrophic non-unions.
Hypertrophic non-union fractures show abundant callus formation without union and
atrophic non-union fractures show little or no callus. These conditions are thought
to be a result of an adverse mechanical environment or a failure of the biology,
respectively [5]. It has been suggested that non-unions may result from characteristics
of the fracture, iatrogenic factors or patient factors. It has even been shown that
smoking has a detrimental affect on fracture healing [6].
1.2.4 Intervention Strategies
1.2.4.1 Normal Fracture Intervention
The nature of intervention is dependent on the nature and severity of a fracture. There
are only ever three reasons to immobilise a fracture:
1. To prevent displacement or angulation of bone fragments.
2. To prevent movement that might interfere with union.
3. To relieve pain.
Intervention is generally kept to a minimum where possible and natural physiological
processes are allowed to progress.
1.2.4.2 Non-union Fracture Intervention
Cases where physiological processes fail to achieve a suitable outcome require a
greater degree of intervention. Hypertrophic non-union fractures are treated with
rigid immobilisation as the problem is thought to be mechanical. Atrophic non-union
fractures have limited treatment options. Fixation can be improved or the end-layer of
bone could be removed to provide raw ends for healing. Another option in the use of
bone grafts.
5
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Bone grafts can be of four general types: Autologous, allogeneic, xenogenic or
synthetic. Each have their own advantages and disadvantages. The principle of a
successful graft is to provide osteoconduction, osteoinduction and (for autografts)
osteogenesis. Bone grafting can be particularly effective since bone has the ability to
completely regenerate due to ongoing remodelling.
Autografts Autologous bone grafts involve utilising bone obtained from the same
individual recieving the graft. Autografts are currently considered the clinical gold
standard. The best grafting success rates have been achieved with vascularised
autografts [7]. Bone is harvested from a non-essential area such as the iliac crest. This
method avoids issues of tissue rejection. Implanted tissue has osteogenic potential
but additional operative sites are required for harvesting which can lead to pain and
complications [8]. There is also a limited supply of tissue [9, 10].
Allografts Allogeneic bone grafts negate the need for a donor site, mitigating the
associated complications. Allografts are obtained from cadavers and can be fresh,
freeze dried or demineralised and freeze dried. Bone banks specialise in preparing
these grafts. The failure rate of grafts from banked bone is higher than that of autografts
and has been quoted at 20–35 % [11]. As with any allogeneic therapy there is always a
risk of pathogenic infection.
Xenografts Xenogenic materials are less common and currently under evaluation.
The most common source is bovine. Due to the pathogenic risks, xenogenic materials
are deprotinated leaving a mineral structure that has a chemical composition and
structure almost identical to human bone [12]. These materials are regarded as
osteocompatible fillers [12].
Synthetic Grafts A variety of synthetic materials are used in orthopaedic surgeries.
These can be broadly divided into two categories: Ceramics and polymers. Ceramics
are by far themost common, these include glass ceramics [13, 14], calcium sulphate [15],
calcium phosphate [16] and hydroxyapetite [17]. Polymeric alternatives are a relatively
new option. The only commercial polymeric product graft at this time is HEALOS R©
(DePuy Synthes). This consists of cross-linked collagen coated with hydroxyapetite to
improve biomimicry of the material structure.
Since these materials are not bone-derived, a mechanical property mismatch is a
problem. This can lead to implant failure and tissue damage [18]. These materials lack
6
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functionalities that encourage tissue integration and self-repair. Methods are currently
under investigation that impart bio-functionality onto these otherwise inert synthetic
materials [19, 20]. It is hoped that this research will lead to highly available bone graft
substitutes with a high degree of long-term implantation success.
Here lies the niche to be exploited. Autografts, the clinical gold standard have good
efficacy but limited availability, as do allografts. There is a growing need for synthetic
materials with greater efficacy.
1.3 Growth Factors
One of the reasons autografts are thought to be so effective is that they contain the
necessary signalling molecules required for repair and vascularisation [21]. These
signalling molecules are known collectively as growth factors.
1.3.1 Overview
Growth factors are proteins that serve as signalling agents for cells. They play a key role
in influencing and regulating cellular processes such as proliferation, differentiation
and matrix synthesis. Recent advancements of recombinant protein technologies have
increased the level of interest for using growth factors as therapeutic agents [22]
particularly in bone engineering [23].
Growth factors act on cells by binding to specific surface receptors. This induces an
intracellular signalling system to convey a message to the nucleus which then induces
a biological response (Figure 1.2).
The most important growth factors for applications in bone regeneration include
various Bone Morphogenetic Proteins (BMP’s), Vascular Endothelial Growth Factor
(VEGF), Platelet Derived Growth Factor (PDGF), Insulin-like Growth Factor (IGF),
Fibroblast Growth Factor (FGF) and Transforming Growth Factor β (TGF-β) [20].
For the purpose of this thesis, three of these growth factors have been selected for
study: VEGF, PDGF and one of the BMP’s. The two important events during a fracture
repair are neovascularisation and osteogenesis. VEGF and PDGF are thought to be
crucial in the formation of successful vasculature [24], recent literature suggests the
synergismof these growth factors to be important [25]. BMP’s are themostwell studied
set of growth factors in bone regeneration. Unlike other growth factors, BMP’s can be
osteoinductive [26].
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Figure 1.2: Diagramatic representation of how growth factors affect cell activity.
The ligand (growth factor) binds to the extracellular domain of the
receptor. The intracellular domain of the receptor then activates a signal
transduction system. A transcription factor binds to the DNA and induces
the expression of a new gene. Figure drawn by the author, Giles Kirby.
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1.3.2 Bone Morphogenetic Protein
Bone morphogenetic proteins (BMP) are members of the TGF-β superfamily. The
osteoinductive effect of these molecules was first observed in the mid 1960’s. Dr.
Marshall Urst demonstrated the induction of new ectopic bone from decalcified bone
matrix [27]. BMP’s have a powerful ability to induce orthotopic and ectopic new bone
formation [28]. Of particular interest are BMP-2, BMP-4 and BMP-7 (Also known as
Osteogenic Protein-1 (OP-1)). These molecules have been reported to have a strong
efficacy in inducing bone formation [29–31].
Modern recombinant protein technology has allowed us to elucidate the effect and
importance of specific proteins. BMP-2 was the first to show it could induce new bone
and cartilage formation [32].
Bone morphogenetic proteins are intrinsically stable proteins due to their tightly-
folded, disulphide stabilised structure. This makes them excellent candidates for
therapeutic products. The stability of lyophilised BMP is thought to be in the order
of years [23].
1.3.3 Vascular Endothelial Growth Factor
Vascular endothelial growth factor (VEGF) is thought to stimulate angiogenesis and
vasculogenesis. It creates blood vessels during embryo development and during
tissue repair. Over expression of VEGF is associated with tumours and much of
our knowledge of VEGF comes from research into cancer. The structure of VEGF
was determined in 1989 and published simultaneously by two groups studying what
they thought to be different molecules [33–35]. One was looking at endothelial cell
mitogenesis and the other, vascular permeability. The 6 isoforms of VEGF were later
elucidated. Each isoform has a different number of amino acids due to alternative
splicing of VEGF mRNA. These different isoforms (121, 145, 165, 183, 189 and 206)
have differing levels of solubility and extra-cellular matrix (ECM) affinity.
1.3.4 Platelet Derived Growth Factor
The structure and function of Platelet derived growth factor (PDGF) is similar to that of
VEGF hence they are both said to be in the PDGF/VEGF family [36]. PDGF, like VEGF,
is composed of a disulphide linked polypeptide dimer. There are two forms of PDGF; a
and b. This leads to three dimeric versions; aa, bb and ab. PDGF plays an important role
in wound healing. This is seen from three different approaches: The effect of PDGF
9
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on cell cultures, the presence of PDGF and PDGF receptors during wound healing and
topical application of PDGF to healing wounds [37].
PDGF stimulates mitogenesis and chemotaxis of fibroblasts, endothelial and smooth
muscle cells [38, 39]. This enhances stability of early vasculature and is thought to be
crucial in generating stable vasculature [40].
1.3.5 Clinical Use
1.3.5.1 Platelet Derived Growth Factor
Diabetic ulcers seem an ideal candidate for angiogenic growth factors. This is a
pathological environment and regeneration is inhibited by the ischemic nature. It
seems logical that if we could induce angiogenesis, thismight increase the rate of repair.
In December of 1997 the U.S. Food and Drug Administration (FDA) granted approval
for the use of REGRANEX R© (becaplermin) gel for the treatment of diabetic foot ulcers.
The active ingredient (becaplermin) is a form of PDGF-BB.
A clinical study in 1998 demonstrated that the healing rate for diabetic ulcers (in
contrast to a negative control) was significantly higher [41] and a cost-effectiveness
study in 2001 indicated that REGRANEX exhibited a ‘favourable economic as well as clinical
profile’ [42]. However at this early stage, there was no large clinical trials comparing
REGARNEX to the clinical gold standards for treatment. History tells us that for a new
healthcare product to become successful it must be more efficacious or cheaper (ideally
both) than the clinical gold standard.
A randomised clinical trial was published in 2005 comparing REGRANEX to OASIS. The
OASIS wound dressing consists of acellular porcine small-intestine submucosa. This
graft significantly stimulates wound closure [43]. The results from this comparison
indicated that the incidence of full thickness diabetic foot ulcer healing was signifi-
cantly higher for groups treated with OASIS than REGRANEX (p=0.055) [44]. It should
be noted that the sample size was too small for this result to be truly representative but
the publication of this paper reflected badly on REGRANEX.
In 2008 the FDA issued a warning that there as an increased risk of death from
cancer from patients who used three or more tubes of REGRANEX although the risk
of new cancers was not increased. Due to reported ‘commercial reasons’, REGRANEX was
withdrawn from sale in the UK in June 2011. Currently epidemiological studies are
ongoing to assess cancer risks.
REGRANEX did not employ any kind of controlled release and it is possible that
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high doses (0.01 %) of PDGF-BB were systemically distributed throughout the body
increasing cancer development. Importantly, this therapy indicated clinical benefit
from an angiogenic growth factor therapy. If costs can be reduced and safety increased
then this indicates a potential future for angiogenic growth factor therapies.
1.3.5.2 Bone Morphogenetic Protein
Currently preparations BMP-2 and BMP-7 are under clinical evaluation for use in
spinal fusion. To date, two recombinant human bone morphogenetic protein (rhBMP)
carrier systems have been approved by the FDA for clinical use. These are OP-1
(Stryker R©) and InFUSE
TM
(Medtronic). These deliver BMP-7 and BMP-2 respectively.
Both of these systems utilise a collagen carrier and supraphysiological concentrations
of growth factor (around 1.5 mg per cc). This high level of BMP within these therapies
has been an ongoing concern and in 2008 the FDA issued a public health notification
regarding life-threatening complications associated with rhBMPs in cervical spine
fusion. Use in spinal fusion has demonstrated similar efficacy to that of autografts [45].
BMP-2 is the most researched and published osteoinductive protein and InFUSE is
also indicated for use in fresh tibial fractures, and oral maxillofacial bone grafting
procedures. Spinal fusion models have consistently shown rhBMP-2 to be as good
as (or better than) autogeneous bone [46, 47]. The success of a randomised clinical trial
involving 279 patients [48] led to FDA approval of InFUSE in 2002. For nearly 9 years,
industry sponsored studies reported the clinical benefits of rhBMP-2 in spinal surgeries
but in 2011 a damning review was published [49]. Thirteen industry-sponsored
reviews of rhBMP-2 safety and efficacy showed that there were no rhBMP-2 associated
adverse events. It was found that these studies had potential methodological bias,
specifically in reporting donor site pain.
As early as the year 2000 when initial lubmar fusion clinical trials were taking
place [50, 51] it was clear that adverse events resulting from rhMBP-2 could not be
well predicted. This is because the expression of BMP-2 is not limited to fracture
inflammatory environments causing osteoinduction. It is present in other pathways
including abnormal growth signalling pathways and the induction of an altered
immune response [52, 53]. Accordingly, in 2002 the following was published in a
review:
‘Safety issues associated with the use of bone morphogenetic proteins in
spine applications include the possibility of bony overgrowth, interaction
with exposed dura, cancer risk, systemic toxicity, reproductive toxicity,
11
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immunogenicity, local toxicity, osteoclastic activation, and effects on distal
organs.’ [53]
The industry sponsored studies that followed failed to verify any of these risks.
In 2008 the FDA issued a public health notification of ‘Life-threatening Complications
Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine.’. This
resulted from a number of independent reports noting complications from using
rhBMP-2 in cervical spinal fusion. These included soft tissue swelling and a compro-
mised airway [49, 54, 55].
These complications could be associated with theorised toxic dosing of BMP-2. They
beg the question; was the dose of BMP too high? Once again, the therapeutic benefit
of a growth factor therapy have been shown but complications have arisen potentially
related to dosing.
1.4 Scaffolds
1.4.1 Overview
Scaffolds are used in tissue engineering approaches for a number of reasons. Scaffolds
are space filling agents that can be used to deliver therapeutic molecules or cells.
Scaffolds can also take on the role of the extracellular matrix (ECM), presenting
necessary anchorage and stimuli so that cells perform as desired. The mechanical
properties of the extracellular matrix is a crucial factor affecting cellular behaviour.
It has been suggested that to create functional equivalents for human tissue, tissue
engineered solutions must recreate physical, mechanical and chemical properties of
the native environment. In this way we can try to replicate the complex interactions
between cells and theirmicroenvironments that influencemorphogenesis, function and
regeneration [56, 57].
Extracellular matrix (ECM) not only provides structural support and protection for
cells, it also contains physical, chemical and mechanical cues which influence cell
behaviour. The ECMmodulates cellular behaviour and in turn cells remodel the ECM.
This is a complex and dynamic process. The ECM is highly hydrated and contains a
number of soluble and insoluble factors. Concentration gradients within the ECM play
an important role in chemotaxis [58, 59], morphogenesis and wound healing [60–62].
An ideal tissue engineered solution should attempt to replicate these features.
When attempting to repair a soft-tissue environment, a soft scaffold with simi-
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lar mechanical properties is desired. For these applications hydrogels are often
utilised [24, 63–67]. Hydrogels have been explored for their potential to deliver cells
and therapeutic molecules.
Osseous tissue usually requires a stiffer scaffolds material to provide structural
support and direct cell behaviour accordingly. Current grafting options are discussed
in Section 1.2.4.2. Autografts intrinsically contain ideal combinations of cells and
bioactive molecules. In addition, the cells have the potential to continue to deliver
therapeutic levels of bioactive molecules conducive to physiological regeneration. In
contrast synthetic alternatives are relatively inert. Attempts have beenmade to include
bioactive molecules [19, 68] to increase efficacy of potential therapies but these types of
grafts are poor delivery substrates for cellular therapy options. It seems that without
the ability to deliver prolonged physiological levels of the correct growth factors, the
efficacy of osteogenic scaffolds will remain limited.
1.4.2 The Future of Scaffolds in Bone Healing
Current synthetic graftingmaterials are generally ceramics and used as graft extenders.
In this way they increase the bulk volume of an autograft, minimising the amount
of material that requires harvesting. Modern chemical and fabrication techniques
are being applied to biodegradable polymers (natural and synthetic) in the hopes
of generating grafts and implants with more suitable mechanical and biological
properties.
It is hoped that one day fully synthetic scaffolds with appropriate molecular cues
will become clinical gold standards, negating the problems associated with autologous
harvesting.
A collagen based material was the first clinical polymeric alternative (HEALOS R©). This
material is no worse than autologous grafting in lumbar spinal fusion [69]. In addition
cellular infiltration into the porous structure has been demonstrated [70]. Since the
degree of cross-linking can be modified, this affects porosity, cellular infiltration and
ultimately mechanical strength can be tailored. This provides a far higher level of
control over the final tissue than can be achieved with current methods.
Other polymers under investigation for use is bone repair are the aliphatic polyesters
polycaprolactone (PCL), polymers of lactic acid (LA) and glycolic acid (GA) and the
copolymer poly(lactic-co-glycolic acid) (PLGA). Lactic acid has two stereoisomers,
giving rise to three forms of LA polymer: L-LA, D-LA and DL-LA. PLGA is of particular
interest because by altering the ratios of monomers the degradation rate can be tuned
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(Figure 1.3).
Porosity is one of the key factors for bone grafting. This is the means by which cells
and nutrients infiltrate the scaffold and it is well known that the degree of porosity
affects the rate of integration and the final volume of regenerated bone [72]. It has been
suggested that an interconnected porosity greater than 75 % is required to facilitate
adequate vascularisation and nutrient diffusion [73]. A number of methods have
been explored to generate porous polymeric structures. These include supercritical
foaming [73, 74], fused deposition printing [75, 76], salt leaching [77, 78] and various
microparticle composites [79, 80].
It is hoped that by combining the correct materials, fabrication methods, bioactive
molecules and maybe even cells, that synthetic scaffolds could exhibit regenerative
efficacy greater than or equal to autografts.
1.4.3 Structural requirements
As important as issues such as porosity and biocompatibility are, it is important
not to forget that this is only half the story when looking specifically at bone tissue
engineering. The structural properties of these scaffolds are of utmost importance
to support necessary load bearing and provide the right mechanical stimuli for bone
regeneration.
A negative correlation between porosity and mechanical strength has been demon-
strated [81, 82] so there will always need to be a compromise between porosity and
mechanical strength for scaffolds aimed at different anatomical regions. It is accepted
that the stiffness of a fracture fixation has an important influence on bone regeneration.
A flexible fixation can lead to callus healing [83] or worse, nonunion [84]. It is also
hypothesised that a degree of interfragmentory movement is needed as a stimulus for
bone regeneration and this is a focus of current research [85, 86].
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Figure 1.3: Half-life of PLA and PGA homopolymers and copolymers implanted in
rat tissue [71].
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1.5 Growth Factor Delivery fromMicroparticles
1.5.1 Overview
The purpose of a delivery system is to deliver a particular dose of something to a
particular location at a specific time. The delivery of a bioactive molecule such as a
growth factor can be done in several ways. The simplest way to deliver a growth
factor involves simply injecting it as a solution into a site. Such approaches have
shown significant effects. For example direct injection of fibroblast growth factor into
porcine cardiac muscle increased the number ofmicro-vessels [87]. Although this direct
approach can work in some cases there will always be clinical concerns over growth
factor migration and toxicity at supraphysiological levels. Supraphysiological levels of
growth factor are used to try and mitigate issues of a short half life (Table 1.1).
Clinical examples of this high dosing are Medtronics InFUSE
TM
and Strykers OP-1.
Growth factors are generally thought to have an effect at concentrations in the order
of picograms to nanograms. This is sufficient to generate a cellular response [88].
These systems deliver growth factors in the order of hundreds of micrograms to
milligrams (per millilitre) in an attempt to prolong therapeutic levels. This has severe
cost implications and will only extend the active dose by a matter of days.
A number of marketed formulations for therapeutic proteins utilise micro/nano
particles/spheres (Table 1.2). These systems protect therapeutic proteins within
polymeric matrices in an effort to maintain stability and/or increase the duration
between administrations. It should be noted that none of these systems are designed
specifically to administer proteins to a particular site of interest.
A number of growth factor delivery systems have been published for the purposes of
tissue regeneration/repair, many based on microparticles. This section will focus on
hydrophobic polymeric microparticles of lactic and glycolic acid. Polymers derived
from D,L-lactic and glycolic acids are by far the most explored for the delivery of
therapeutic proteins.
Poly(D,L-lactic-co-glycolic acid) (PLGA) is generally fabricated through the ring-
opening polymerisation of lactide and glycolide cyclic dimers. PLGA has an extensive
history of research and clinical use. The most well known use is sutures such as
Vicryl R©. PLGA is also used in grafts, implants, prosthetic devices and microparticles
for drug delivery. PLGA is considered to be biocompatible, bioresorbable and
non-toxic. PLGA (and other aliphatic polyesters) degrade mainly via hydrolytic
mechanisms [89, 90]. It is possible that there is some enzyme catalysis taking place
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in vivo [91] but the evidence is not convincing. Degradation products, lactic acid and
glycolic acid, undergo degradation through the Krebs cycle to form harmless water and
carbon dioxide [92, 93].
Growth Factor Half-life
VEGF 50 minutes [94]
PDGF 2 minutes [95]
BMP-2 7–16 minutes [96, 97]
Table 1.1: Serum half-life of three growth factors of interest.
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Drug Trade name Route Application
Leuprolide acetate Lupron depot R© 3-month depot suspension Prostate cancer
Recombinant human growth hormone Nutropin depot R© Monthly s/c injection Growth hormone deficiency
Goserelin acetate Zoladex R© s/c implant Prostate cancer
Octreotide acetate Sandostatin LAR R© depot Injectable s/c suspension GH supression anticancer
Triptorelin Decapeptyl R© Injectable depot LHRH agonist
Recombinant bovine somatropin Posilac R© Oil based injection To increase milk production in cattle
Table 1.2: Marketed formulations of proteins from biodegradable microparticles. Adapted from Sinha et al [98].
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1.5.2 Growth Factor Stability
Growth factors are fragile. As well as the primary structure, many rely on complex
secondary, tertiary and sometimes quaternary folding for their biological activity. This
means that they are particularly susceptible to detrimental conditions present during
micro-encapsulation and release.
In a physiological situation, growth factors are expressed by cells. The rapid expression
and metabolism of growth factors ensures that the combinations and concentrations of
growth factors are relevant to the changing physiological situation. Some experimental
in vivo approaches have utilised transduced cells in order to up-regulate expression
of particular growth factors [40]. This is a good tool to assess the effects of growth
factors or even the effects of growth factor combinations but the level of dosing is
relatively imprecise and this approach has too many safety concerns to become a
clinical approach in the near future.
The FDA defines a stable pharmaceutical as one that deteriorates less than 10 % in two
years [99]. Encapsulation of a growth factor within a delivery vehicle involves three
stages in which the growth factor must remain stable: Fabrication, storage and release.
Proteins can degrade by a number of mechanisms [100–106]. A lyophilised protein
based therapeutic can remain stable for months or even years at ambient tempera-
tures [107]. The stages with the highest potential for protein denaturation are during
fabrication and release. These can involve aqueous/organic interfaces, temperature
changes, agitation, hydrophobic surfaces, detergents or breakdown products from the
degrading carrier system. Each of these must be addressed. The key to achieving
release of a stable protein is understanding the conditions involved in a particular
system.
One such approach achieved stable release of recombinant human growth hormone
(rhGH) over a 1 month period [108]. Stability was achieved by complexing the
rhGH with zinc. This reduced the solubility of the hormone thus its susceptibility
to degenerative mechanisms. Although this approached worked, systems that rely
on modification of the encapsulated active will always be dependent on the type and
functionality of that active. To develop a system that is able to deliver multiple growth
factors in multiple situations will require an approach that addresses the detrimental
conditions independent of protein manipulation. This approach would have a greater
number of applications.
An example of this approach has been to mitigate the acidic microenvironment within
PLGA matrices. Acidity results from accumulation of lactic acid and glycolic acid
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breakdown products. This acidic environment causes protein unfolding leading
to aggregation as well as acid-catalysed hydrolysis [109]. Magnesium hydroxide
(Mg(OH)2) has been incorporated within the polymer to try and neutralise this
damaging environment. This approach has shown a greater overall release of bovine
serum albumin (BSA) [110] indicating reduced aggregations. This approach has proven
effective at mitigating pH issues in several studies [111, 112], but the inclusion of salts
could themselves be a risk factor leading to protein instability. Some proteins become
unstable at high salt concentrations [113]. This may cause denaturation problems
during a lyophilisation process.
An acidic micro-environment within PLGA microparticles may not even be an issue in
certain situations. Degradation of larger PLGA devices tends to be hetrogeneous [90,
114, 115]. This is because the build up of acidic monomers in the core leads to an
increased rate of hydrolysis through acid catalysis. The degradation of smaller devices
such as microspheres under 300 µm appears to be more homogeneous [116]. As
previously mentioned, the acidic microenvironment within degrading PLGA may be
detrimental to protein activity but if the size of the delivery device is kept small enough
then this issue could potentially be mitigated.
1.5.3 Microparticle Fabrication Techniques
1.5.3.1 Solvent Evaporation and Solvent Extraction
Single Emulsion As the name suggests, this process involves a single emulsification
step and in the case of hydrophobic polymers, an oil-in-water (o/w) emulsion. The poly-
mer is dissolved in an organic solvent that is immiscible with water. Dichloromethane
(DCM) is the most commonly used. A lipophilic drug can then be also dissolved
into the organic phase but for hydrophilic growth factors another technique must be
used. A method that has shown to work with model proteins involves micronising the
protein then dispersing it within the organic phase [117, 118]. This is referred to as a
solid-in-oil-in-water (s/o/w) emulsion. The potential for higher entrapment efficiencies
have been reported using this technique in preference of a double emulsion method.
This oil phase is emulsified within a larger aqueous phase. A surfactant such as
poly(vinyl alcohol) (PVA) is generally used to stabilise this emulsion while the organic
solvent either evaporates or is extracted by a leaching method. A stable emulsion is
important for high entrapment efficiencies and regular particle morphology [119]. The
result is a suspension of hardened polymer microparticles in an aqueous solution. The
microparticles are collected by centrifugation, sieving or filtration. The microparticles
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are then dried to produce a free-flowing product.
This process method favours lipophilic drugs such as steroids [93, 120]. Hydrophilic
proteins have a tendency to diffuse into the aqueous phase resulting in low entrapment
efficiencies. An approach to mitigate this issue is an oil-in-oil (o/o) technique. A water
miscible solvent such as acetonitrile is used to dissolve the polymer as well as the the
hydrophilic drug. This is then emulsified within a different oil. There are concerns that
this environment could be damaging to fragile growth factors.
Double emulsion This method utilises two emulsification steps. This is a water-
in-oil-in-water (w/o/w) method and is particularly suited for the encapsulation of
hydrophilic molecules (such as growth factors) within a hydrophobic polymer (such
as PLGA). A schematic of this process can be found in the methods chapter (Sec-
tion 2.3.3, Page 40). The growth factor is dissolved in water (or a buffered solution)
and this is emulsified within an organic phase that contains dissolved polymer. Once
again, DCM is the most common solvent. This is the first emulsion step. The next
emulsion step sees thisw/o emulsion emulsified in a larger aqueous phase, once again a
surfactant is often used to stabilise this emulsion while the organic solvent is extracted.
The microparticles are then collected and dried.
This process is the most popular for the encapsulation of growth factors. A large
number of parameters can be adjusted to influence growth factor release rates and
entrapment efficiencies. The deleterious environments inherent to this process are also
well documented. The most significant during the fabrication stage is the oil/water
interface. This can cause denaturation of proteins and growth factors [103]. The
most common approach is the inclusion of an excipient to competitively block the
interface [102, 104, 121–123].
Emulsification Techniques Formation of an emulsion requires the combining of
immiscible solvents. Common methods impart energy into the system in the form
of shearing fluidic forces. Different emulsification techniques lead to different mi-
croparticle sizes, morphologies and polymer crystallinity. Themost publishedmethods
are sonication, microfluidics, high pressure mixing and mechanical agitation such as
stirrers, impellers and baffles.
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1.5.3.2 Phase Separation (coacervation)
The word coacervate is derived from the Latin coacervare, meaning to assemble together
or cluster. A coacervate is formed when a substance is pushed out of solution by
another substance. For example the solubility of PLGA could be reduced by the
addition of another component. This results in two phases: the polymer-containing
coacervate and the supernatant. Typically poly(dimethylsiloxane) is added to PLGA
dissolved in DCM. This forms the coacervate droplets [124]. These polymer droplets
then coat the suspended drug/growth factor particles. The rate of addition of the
precipitating agent directs the rate of polymer droplet formation. This should be done
slowly so the polymer evenly coats the drug particles.
Since this process lacks any emulsion stabiliser, agglomeration of particles is a prob-
lem [93]. This process utilises harsh solvents. These could be damaging to growth
factors or other fragile proteins.
1.5.3.3 Spray Drying
Spray drying involves mild conditions, it less dependent on the solubility of the drug
and is considered easier to scale up [120, 125, 126]. The drug is dispersed within an
organic solvent, containing the polymer. For hydrophilic compounds a w/o technique
is sometimes used [127]. This mixture is sprayed into a warm, dry environment. The
resulting microparticles can be collected and dried further.
This method has been used to encapsulate heparin, a relatively large hydrophilic
glycosaminoglycan, into PLGA microparticles. The resulting microparticles were 2–
5 µm in diameter and released heparin for up to 50 days in vitro [127].
A variation on this method is known as cryogenic atomization. This method involves
spraying the polymer/drug emulsion and rather than being dried they are snap-frozen.
The DCM is later extracted. This method has been used to encapsulate the model
protein ovalbumin into hydrophobic polymers forming microparticles approximately
20 µm in diameter [128]. Western blot analysis verified that the released ovalbumin
was active and this method is reported to achieve higher entrapment efficiencies than
a double emulsion method [129].
1.5.4 Sterilisation
It is important that the microparticle product is sterile in order to carry out long-
term release studies, in vitro or in vivo analysis. There are two ways to approach
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this: Terminal sterilisation or aseptic manufacturing. Fabrication techniques such
as sonication or microfluidic emulsion methods are particularly suited for sterile
fabrication as they are enclosed. Other methods can be carried out in a sterile way
but it can be difficult for laboratory-scale production. Standard sterilisation techniques
are outlined (Table 1.3).
Steam and dry heat methods are not suitable for growth factor loaded PLGAmicropar-
ticles because the relatively low Tg temperatures of PLGA could lead to particle de-
formation. Elevated temperatures may also contribute to growth factor denaturation.
Gas sterilisation is a popular choice for thermoplastic polymers that are degradable
by hydrolysis. However, there are concerns that any chemical sterilisation methods
may leave residual sterilisation agent behind in harmful quantities. It is important that
polymeric systems are adequately degassed and aerated following sterilisation with
ethylene oxide [131].
Gamma irradiation is a popular choice for biomaterials and pharmaceuticals. It is a fast
effective method with a high degree of penetration. If this technique is used for PLGA,
the reduction of molecular weight should be considered (Figure 1.4). It has been shown
that that gamma irradiation can cause radiolytic scission of PLGA [132, 133]. These
shorter chains will have an increased hydrolytic degradation rate [134] therefore the
potential for an increased rate of growth factor release.
A common approach for laboratory-scale biomaterials involves fabrication under a
clean environment and ultraviolet irradiation [76]. This is suitable for non-clinical
applications but the issue of sterility must be considered for any materials with
potential for clinical translation.
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Sterilisation technique Advantages Disadvantages
Steam (high pressure–120 ◦C-135 ◦C) No toxic residues Deformation of microparticles (temperature above Tg), hydrolytic degradation
Dry heat (160 ◦C-190 ◦C) No toxic residues Deformation of microparticles (temperature above Tg)
Radiation High penetration, fast Radiolytic scission of polymer and/or growth factor
Gas sterilisation (ethylene oxide) Low temperature process Long process due to degassing, residues are toxic
Table 1.3: Standard sterilisation techniques and their applicability to PLGA. Adapted from Kyriacos et al, 1996 [130].
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Figure 1.4: Effect of gamma sterilization on the molecular weight distribution of
PLGA microparticles. Published by Hausberger et al, 1995 [134].
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1.5.5 Characterisation of Growth Factor Release
1.5.5.1 Release in vitro
The release of growth factors from microparticles is dependent on a number of
formulation and processing variables. To estimate how these microparticles will
perform in vivo, in vitro release studies are carried out. These studies can assess
total protein release or the activity of some proteins. Total protein can be assessed
colorimetrically using an assay such as the Bradford assay [135] or a bicinchoninic
acid assay [136]. The activity of released proteins can be quantified enzymatically
or using a structurally dependent assay such as an Enzyme-Linked Immunosorbent
Assay (ELISA). Cellular assays can also be used to identify the activity and sometimes
concentration of bioactive molecules by looking at certain markers expressed by the
cells.
So that the protein release frommicroparticles will be representative of their behaviour
in vivo, consideration must be paid to the intended in vivo site and the best way to
recreate that in the laboratory. Generally, this involves physiological temperature, a
buffer to maintain physiological pH and some kind of agitation. For a full review on
how to obtain complete release from PLGA microparticles see Gitea et al, 2008 [137].
1.5.5.2 Release in vivo
Assessment of in vivo release relies on measuring physiological responses to released
cues in contrast to control conditions. Assessments like this in animal models are the
only way to determine how a particular therapeutic biomaterial will perform clinically.
Common measures of the repair of an osseous defect are radiography, biomechanical
testing, micro computerised tomography and histological analysis [76]. In this way the
mineral density/structure,mechanical strength and cellular presence/morphology can
be assessed to give an indication of whether a particular technique was significantly
better than another.
1.6 Aim
1.6.1 Scientific Need
The importance of angiogenesis during an osteogenic repair is well understood. The
growth factors that enhance angiogenesis and osteogenesis are also well understood.
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Current research is assessing various combinations of these growth factors during
osseous repair. There is currently a lack of scientific data that assesses these growth
factor combinations in large mammal models over the duration of a full fracture repair.
There is also a lack of standardised, well defined systems to deliver different growth
factors while addressing issues of denaturation and therapeutic dosing.
1.6.2 Aims of Thesis
This thesis aims to address two goals: To generate and validate a system for delivering
growth factors and develop the materials and processes to a stage where they can be
applied into an in vivo model.
1.6.2.1 Delivery System
The formation of a polymeric microparticle system for the delivery of growth factors
is proposed. This will be formulated and fabricated in such a way as to protect un-
released growth factor from hydrolytic and enzymatic degradation. The microparticles
will modulate the duration and concentration of growth factor release and control the
location of growth factor action. The system should also be applicable to multiple
growth factors so the release kinetics should not be dependent on growth factor
characteristics such as molecular weight and isoelectric point.
By protecting the un-released growth factor structure it is hypothesised that issues
associated with a short in vivo half life can be mitigated. By extending growth factor
half lives the therapy could impart a longer duration of biological activity, reduce the
need for multiple administrations and potentially reduce the total amount of growth
factor required to achieve a desired response. A controlled release system has the
potential to minimise the total amount of growth factor required while conserving the
therapeutic effect.
It is hoped that by maintaining a dose of growth factor in a therapeutic range, negative
effects resulting from toxic concentrations can be avoided. The biomimicry of a
therapeutic concentration of growth factor may also increase the efficacy of this type of
system.
The targeted nature of a microparticle system aims to limit the location of action of
released growth factors to a region of interest or repair. If systemic dosing can be
avoided it is hoped that risks such as the cancer concerns over REGRANEX can be
reduced.
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It is hoped that one system that can be formulated to achieve different release profiles
will be a viable option for clinical therapies. For example if a short and a long duration
of release are required within a site then a mixture of microparticles will be far easier
to store, manipulate and administer than composite therapy such as one involving the
mixture of a hydrogel and a hydrophobic polymer device.
These needs will be addressed by combining different formulations of PLGA with
a more hydrophilic plasticiser. This should provide a greater level of control over
hydration rates than current approaches thus greater control over the release of
growth factors. The microparticle fabrication process will be tailored to be robust and
consistent and also to minimise environments damaging to growth factor structure
and activity. The formulation will be augmented with an albumin stabiliser to help
protect the growth factor structure and also to competitively block the deleterious w/o
interface. The addition of an albumin excipient will also enable the concentration of
growth factor within the microparticles to be adjusted but the ratio of PLGA to protein
to remain the same (though adjustment of albumin levels). This keeps the process
robust as it is suspected that changing the ratio of PLGA to protein could affect release
rates.
1.6.2.2 Preparation for assessment in vivo
This microparticle delivery systemwill be developed with the intention of delivering a
combination of angiogenic and osteogenic growth factors to a segmental defect model
at levels and a duration similar to a physiological repair environment.
It is hypothesised that the induction of angiogenesis early during the repair processwill
lead to a more rapid and a more complete repair. If this is the case then this research
could lead to the next generation of bone repair strategies delivering combinations of
growth factors at physiological levels.
The microparticle growth factor delivery system will be used to tailor populations of
microparticles to deliver VEGF, PDGF and BMP-2 accordingly. The release will be
verified and microparticles will be combined with an osteoconductive and structurally
supportive scaffold ready for future studies.
1.6.3 Objectives
The objectives required to achieve these goals can be broken down into three main
strategies (corresponding with results chapters) and a series of sub-objectives.
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1. Develop a polymeric system for growth factor release.
• Fabricate PLGA microparticles with consistent size distributions.
• Encapsulate model protein and assess encapsulation efficiency.
• Assess release of protein under simulated physiological conditions.
• Deduce how changes in formulation equate to protein release.
• Assess the activity of a model protein.
• Ensure replacement of the model protein with a growth factor has no
significant effect on the release profile.
2. Verify the biological activity of released growth factor.
• Culture cells in vitro in the presence of growth factor releasing microparti-
cles.
• Assess biological changes resulting from the released growth factor.
3. Implement this system to make it suitable for an in vivo model.
• Select microparticle formulations to deliver growth in the required way.
• Fabricate microparticles and validate the protein release.
• Develop a method to combine the microparticles with a scaffold suitable for
a segmental defect.
This thesis begins with the fabrication of microparticles. Can PLGA degradation be
tailored such that protein can be released over just days or for a number of weeks?
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Results I: Microparticle fabrication
2.1 Introduction
This chapter details the selection, optimisation and characterisation of a polymeric
growth factor release system. The main introduction outlined the clinical need for a
growth factor delivery system and how PLGA was selected as a delivery candidate.
A more hydrophilic co-polymer was selected as an adjunct to the PLGA. The purpose
of this second polymer was to provide another method to modulate protein release.
Increasing the ratio of the more hydrophilic polymer should increase the rate of water
ingress into the polymer composite leading to increased protein diffusion through
pores and micro-channels. It was also speculated that this water ingress would
increase the rate of PLGA bulk degradation due to hydrolytic mechanisms. It has been
demonstrated that polyethylene glycol (PEG) inclusion into PLGA microparticles has
been able to modulate release profiles [138, 139]. A PLGA-PEG-PLGA triblock copoly-
mer was selected for this purpose because of its documented biocompatibility [140]
and use in delivery systems [66, 141, 142]. The surfactant nature of this copolymer
was also considered, it has been shown that the PEG segmant promotes stability of
proteins [143].
Microparticle fabrication using a double emulsionwater-in-oil-in-water (w/o/w) solvent
evaporation process has been well investigated for the encapsulation of hydrophilic
molecules of interest within a hydrophobic matrix [144–146]. Our research group also
has prior experience in this technique [147].
Model proteins are often used to develop and evaluate release systems of this nature.
A well selected model protein should have similar physicochemical characteristics to
the active protein of interest as well as a published method to assess the structural
activity of the protein following encapsulation and release. Lysozyme was selected
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in this instance because of its similar characteristics to the growth factors of interest
(Table 2.3, Page 52). Lysozyme also has a well documented activity assay involving the
kinetic breakdown of a bacterial cell wall (Section 2.3.5.4, Page 42).
The main disadvantage to the w/o/w double emulsion fabrication method is a potential
for protein denaturation and aggregation during fabrication. The primary emulsion
step requires an aqueous solution of protein to be dispersed within an organic solvent.
This generates a water/solvent interface. It has been shown that lysozyme unfolds and
aggregates as a result of this interface [103]. This issue must be addressed to ensure
maximum biological activity of an encapsulated growth factor. A potential solution
has been to include excipients with the active protein that are thought to competitively
block the harmful interface [102, 104, 121–123]. Albumins have been shown tomaintain
stability during lyophilization [148], to increase encapsulation efficiency within the
polymer [145] and reduce aggregates [105].
The goal of in vitro release from therapeutic formulations is to replicate (as accurately as
possible) what the in vivo release will be. From this data we can then estimate optimum
formulations and dosages. This is not a simple endeavour. There are a number of
factors to consider. The release media used to assess protein release are generally
buffered solutions that replicate a physiological pH. Most authors favour phosphate
buffered saline (PBS, pH 7.4) at 37 ◦C. Unfortunately, few proteins are stable in these
conditions. Lysozyme, for example, aggregates in these conditions [101, 149] whereas it
can be stabilised in a glycine buffer (pH 2.5) and demonstrated complete release [101].
The pH of a release medium also affects the protein degradation rate; acidic conditions
catalytically affect the degradation of the esters present in PLGA [150].
A system that can be used for the controlled release of multiple proteins with different
rates requires a number of key considerations. Protein release is a combination of three
factors:
1. Burst release – The release of surface bound protein (or protein near to the
surface).
2. Diffusion – Mediated by microparticle hydration/swelling and the presence of
micro-channels.
3. Bulk degradation – The release of physically entrapped protein resulting from
polymer scission erosion.
Inclusion of PLGA-PEG-PLGA can be used to modulate water ingress affecting
diffusion and hydrolytic degradation. In addition the monomer ratios of PLGA
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provide control over bulk degradation rates with minimal effects on hydrophilicity.
A w/o/w fabrication method simply requires that the protein be water soluble, so is
applicable tomany proteins/growth factors. Minimal denaturation of the encapsulated
proteins is critical. The addition of an albumin carrier should provide competitive
protection to the harmful water/oil interface. Release assessment (in vitro) must
accurately mimic the conditions expected in vivo including any protein adsorption,
aggregation or denaturation so that appropriate judgements can be made regarding
a therapeutic dose.
This chapter also introduces another potential application for a growth factor releasing
microparticle system. This system has potential in biomimicry of extracellular matrix
(ECM) as well as elucidating the importance and role of growth factors at a basic
science level.
Concentration gradients have been used in cell-biomaterial screening [151] and to
study cell processes such as migration and angiogenesis [152]. Concentration gradients
of angiogenic factors are important in angiogenesis and neovascularisation causing
endothelial cell migration up a concentration gradient and the sprouting of micro-
tubules [153, 154]. Such gradients are being explored to increase endothelial cell
migration into scaffolds with the aim of minimising necrosis [155]. More long range
growth factor gradients are thought to enable efficient functioning of bones [156].
A number of methods have been developed to create chemical concentration gra-
dients [157]. Most methods produce relative concentrations between two solutions.
These can either be:
• Different concentrations of the same species.
• Concentrations of different species.
• Both the above.
The simplest method to generate a concentration gradient relies on molecular diffusion
through amedium. This requires a source and a sink so that molecules can be passively
diffused [158, 159]. Diffusion can be time consuming so techniques are being developed
to make the process easier such as microfluidic devices [160]. Given sufficient source
and sink volumes, stable gradients can theoretically be maintained for days using
passive diffusion techniques.
Microparticles as growth factor delivery vehicles are being explored for spatiotemporal
applications but there is very little literature regarding the generation of defined
gradients using microparticle delivery. Theoretically microparticles could be a large
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source of growth factors and deliver a steady dose, this would enable the generation
of stable gradients for long periods. This could more accurately mimic in vivo
environments and be useful as both a tool to increase our understanding of cellular
responses to gradients but also as a method to increase the biomimicry within tissue
engineered constructs.
PLGA microparticles have been used alongside silk scaffolds to try and create a
gradient of BMP-2 and Insulin Growth Factor-1 (IGF-1) to study osteochondronic
differentiation of human Mesenchymal Stem Cells (hMSCs) [161]. Differentiation was
observed using the silk scaffolds but not the PLGA microparticles in alginate. It is
possible that the diffusion was too rapid. A system has been demonstratedwith PLGA
microparticles to deliver a concentration gradient of dye with future applications for
growth factor delivery [162].
It is hypothesised that our well characterised microparticles may be well suited for this
application.
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2.2 Aims
The aim was to develop a robust protocol to fabricate microparticles with consistent
size and morphology. This fabrication method had to be suitable for the incorporation
of fragile growth factors with high entrapment efficiencies. Thesemicroparticles had to
exhibit sustained release profiles over different durations depending on the particular
formulation.
A novel PLGA / PLGA-PEG-PLGA polymer system was selected to provide control
over water ingress. The novelty for this piece of research is to vary this polymer
blend in such a way that sustained release of proteins can be executed for different
periods of time. For longer-releasing formulations this involved a protein release ‘hand
off’ from diffusion mediated release to bulk erosion mediated release. To highlight
other potential uses of this system, other methods were briefly explored to deliver and
utilise these microparticles. They have applications in soft tissue regeneration and the
development of more advanced in vitro models.
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2.3 Methods
2.3.1 Synthesis of PLGA-PEG-PLGA
Triblock copolymers of PLGA and PEG were prepared by a ring opening polymeri-
sation of D,L-lactide and glycolide in the presence of PEG with a small amount of
stannous octoate. The process was described by Zentner et al in 2001 [141] and adapted
by Hou et al in 2008 [163]. Under a dry nitrogen atmosphere, polyethylene glycol
1500 (PEG) (Sigma, CAS: 25322-68-3) and Tin (II) 2-ethylhexanoate (Sigma, CAS: 301-
10-0) were heated to 45 ◦C to bring the PEG to a molten state. This was allowed to
equilibrate for 1 hour. Dimers of DL-lactide (Lancaster synthesis, CAS: 95-96-5) and
glycolide (PURAC, Netherlands) were added to the reaction vessel. The temperature
was maintained between 110 ◦C and 150 ◦C for 8 hours. The crude polymer was
purified by dissolving in a minimum amount of cold (2− 8 ◦C) deionised water then
heating to 80 ◦C to precipitate the polymer. The water (containing dissolved unreacted
monomers) was discarded. This process was repeated. The polymer was freeze dried
and stored at −20 ◦C.
2.3.2 Characterisation of PLGA-PEG-PLGA
2.3.2.1 Gel Permeation Chromatography
Gel permeation chromatography is a type of size-exclusion chromatography that
measures the size of molecules and is commonly used to analyse polymers. It provides
data regarding the distribution of molecular mass in a given polymer sample. Notable
arithmetic outputs are the weight average molecular weight (MW) and the number
average molecular weight (MN). MW is a calculation of average molecular weight
that is generally biased towards higher molecular weight molecules whereas MN is an
arithmetic mean that is biased towards lower molecular weight molecules. In a perfect
polymer with a single molecular mass, these averages would be equal. These two
methods for estimating the average molecular weight allow us to assign a numerical
value relating to the degree of molecular weight heterogeneity. This is known as
the polydispersity index (PDI) or heterogeneity index and is calculated as shown in
equation 2.3.1.
PDI = MW/MN (2.3.1)
The PDI is a value greater than or equal to 1. As the PDI approaches 1, the degree of
molecular weight heterogeneity decreases.
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Analysis was carried out using a GPC instrument (PL-GPC 120, Polymer Labs) with
differential refractometer detection. Tetrahydrofuran (THF) was utilised as an eluent
and two columns (30 cm, PolarGel-M) were fitted in series and calibrated against
polystyrene standards.
2.3.2.2 1HNuclear Magnetic Resonance
Proton nuclear magnetic resonance (1H NMR) spectroscopy is a method of identifying
the environment and abundance of protium atoms. This allows for extrapolations of
molecular structure and molecular ratios. The three important pieces of information
obtained from NMR are the chemical shift (δ), the spin-spin coupling and the inte-
gration curve. A higher value of δ is caused by a deshielded protium caused by the
withdrawal of electron density by adjacent atoms. Tables are available for common
functional groups listing δ values. Spin-spin coupling is the result of the magnetic field
of neighbouring atoms splitting the detection peak. This provides further information
as to the structure of the molecule. The integration curve is the area under detection
peaks and directly correlates with the abundance of particular protium environments
within a sample. A typical NMR spectra for PLGA-PEG-PLGA is shown (Figure 2.1).
The molecular structure of PLGA-PEG-PLGA is shown and indicated to illustrate
how the peaks correspond to functional groups. From the integration values at these
functional groups it is possible to calculate the ratio of lactide to glycolide and the ratio
of PLGA to PEG.
Proton Nuclear Magnetic Resonance (NMR) spectra of PLGA-PEG-PLGA samples
were obtained in deuterated chloroform (CDCl3) using an NMR instrument (DPX-300,
Bruker) at 400MHz. A tetramethylsilane (TMS) signal was taken as the zero chemical
shift. Number-average molecular weight, lactide to glycolide ratio and PLGA to PEG
ratio were calculated by integrating the signals relating to each monomer – the CH
and CH3 pertaining to DL-lactide, the CH2 of glycolide and the CH2 of ethylene glycol
(Figure 2.1).
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Figure 2.1: Representative 1H NMR spectrum of PLGA-PEG-PLGA triblock copoly-
mer.
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2.3.3 Microparticle Fabrication
Microparticles were prepared using the well reported technique of double emulsion
solvent evaporation. Briefly a w/o/w emulsion was formed consisting of the aqueous
molecules of interest within an organic solvent containing dissolved polymer within
an aqueous surfactant. This fabrication process is outlined in figure 2.2 on page 40.
Specific details regarding the polymer can be found in table 2.1.
2.3.3.1 Vortex Method
Poly(DL-lactic-co-glycolic acid) (1.00 g) was dissolved in 5ml dichloromethane (DCM)
in a 25ml scintillation vial forming the organic phase. A protein solution consisting of
10mg protein in 100 µl deionised water was added to the organic phase and held on
the vortex shaker at a 45 degree angle for 90 seconds forming the primary emulsion.
This primary emulsion was added to 200ml of 0.3% w/v polyvinyl alcohol in a 250 ml
beaker while being stirred at 300 rpm. This produced the secondary emulsion.
After 4 hours the suspension of microparticles was filtered and washed with 2 l of
deionised water using vacuum filtration and a 0.2 µm filter. The microparticles were
transferred to a 20ml centrifuge tube, snap-frozen using liquid nitrogen and then dried
on a freeze dryer for 24 hours (until dry). Microparticles were vacuum sealed and
stored at −20 ◦C.
2.3.3.2 Homogenisation Method
Poly(DL-lactic-co-glycolic acid) (1.00 g) was dissolved in 5ml dichloromethane (DCM)
in a 30ml PTFE jar forming the organic phase. A protein solution consisting of 10mg
protein in 100 µl deionised water was added to the organic phase and homogenised
for 2 minutes at speed A forming the primary emulsion. This primary emulsion was
added to 200ml of 0.3% w/v polyvinyl alcohol in a 250 ml beaker and homogenised for
a further 2 minutes at speed B forming the secondary emulsion. The beaker was then
magnetically stirred with a 50mm glass encased stirrer bar at 300 rpm for 4 hours.
The suspension of microparticles was filtered and washed with 2 l of deionised water
using vacuum filtration and a 0.2 µm filter. The microparticles were transferred to a
20ml centrifuge tube, snap-frozen using liquid nitrogen and then dried on a freeze
dryer for 24 hours (until dry). Microparticles were vacuum sealed and stored at−20 ◦C.
Homogeniser speed A and B were used to control the resulting microparticle size.
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mole% lactide mole% glycolide Inherent viscosity MW (Da) MN (Da) PDI
(dl/g)
50 50 0.44 56,000 30,000 1.87
85 15 0.45 56,000 32,000 1.75
Table 2.1: Molecular data of the PLGAused formicroparticles. This datawas obtained
from Lakeshore Biomaterials analytical report. Inherent viscosity was
carried out in 0.5% w/v in chloroform at 30 ◦C. These two formulations are
later referred to as PLGA 50:50 and PLGA 85:15
Speeds of 4,000 and 9,000 rpm (respectively) produced a modal particle size of 22− 26
µm and speeds of 2,000 and 2,000 rpm produced a modal size of 70− 100 µm. Lower
homogenisation speeds failed to produce complete and homogeneous emulsions and
higher speeds caused excessive foaming.
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Figure 2.2: Schematic showing the double emulsion method of microparticle fabrica-
tion. This is the same method whether vortex or homogenisation is used
to form the emulsions. This diagram is not to scale.
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2.3.4 Microparticle Characterisation
2.3.4.1 Scanning Electron Microscopy
Microparticles were mounted on 12.7mm SEM stubs (Agar, G301) and adhered using
12mm adhesive carbon tabs (Agar, G3347N). Samples were sputter coated for 4.5
minutes using a Balzers SCD 030 gold sputter coater (Balzders Union Ltd., Leichtenstein)
and imaged using a Jeol 6060LV variable pressure scanning electron microscope (Jeol
(UK) Ltd.) with an accelerating voltage of 10 kV.
2.3.4.2 Size Analysis using Laser Diffraction
Microparticles were sized by laser diffraction using a Coulter LS230 (Beckmann Coulter)
fitted with the optional hazardous fluids module. Background readings (water alone)
were measured and subtracted and the software was loaded with the refractive index
of water (The suspension fluid) and garnet (a mineral with similar optical charcteristics
to PLGA). Samples of microparticles were suspended in double deionised water and
gradually added to the Coulter module until an obscuration of 8-12% was indicated.
Three 30 second runs were averaged and recorded.
2.3.5 Assessment of Protein Release From Microparticles
2.3.5.1 Assessment of Encapsulation Efficiency
Encapsulation of protein within the microparticles was determined using a method
developed by Sah et al [164] and adapted by Morita et al [118]. Microparticles (10 mg)
were incubated in dimethylsulphoxide (DMSO) (750 µl) at room temperature for 1
hour. A solution of sodium lauryl sulphate (0.02 %) in 0.2 N sodium hydroxide (2150
µl) was then added for a further hour. This resulted in a solution of polymer and
protein. This was neutralised using dilute hydrochloric acid and the protein content
was measured using a BCA protein assay (Section 2.3.5.3, Page 42). Appropriate
controls (microparticles with no protein) were used.
2.3.5.2 Protein Release in vitro
Protein was released into phosphate buffered saline at 37 ◦C with agitation from an
orbital stage set at 5 rpm. These conditions were selected tomimic in vivo environments
as closely as possible. Initial release studies using model proteins were released
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as follows. Dry microparticles (50 mg) were combined with PBS (3 ml) in a 15
ml centrifuge tube (Greiner, 188261). This was incubated on the orbital rocker and
the PBS was sampled at regular intervals determined (in part) by the amounts of
protein released and the detection limits of the assay. Sampling involved allowing
the microparticles to settle then completely removing and replacing the PBS. Release
supernatants were stored at −20 ◦C prior to assaying.
Release studies for growth factor loaded microparticles were carried out on a smaller
scale whereby dry microparticles (25 mg) were added to PBS (1.5 ml) in a 1.6 ml
Eppendorf (Sarstedt, 72.690). Work within the group demonstrated that this reduction
in scale had no significant effect on release characteristics (unpublished data).
2.3.5.3 Protein Quantification
Protein was quantified using a bicinchoninic acid (BCA) assay (Thermo Scientific Pearce,
23335). This assay colorimetrically quantifies peptide groups found within protein
molecules [136]. Calibration solutions were custom made to be representative of the
mixture of protein types within the samples and within the same dissolution medium
as the samples, in this case PBS. Calibration plots were obtained for each individual
microplate to account for differences in incubation times and plate anomalies. If
measured protein concentrations were outsude the linearity of the assay (i.e. not within
the calibration plot range) then the samples were appropriately diluted and the assay
repeated. Each sample was assayed in triplicate. Unknown samples were compared
against the calibration plot in the linear range of the assay. Least squares regression
was used to calculate the equation of a trend line based on the calibration samples; this
equation was used to obtain the concentration of unknown samples.
2.3.5.4 Quantification of Active Lysozyme
In 1922 Alexander Flemming first identified lysozyme through its destructive effect on
a suspension of Micrococcus lysodeikticus [165]. Lysozyme breaks down the cell wall of
Micrococcus lysodeikticus by lysing a 1,4 glycosidic bond. The rate of this enzymatic
effect is dependent upon concentration of the lysozyme and the concentration of
Micrococcus lysodeikticus can be determined by measuring the turbidity of the solution
at 450 nm. [Nb, I may move this first bit into another chapter]A variation upon
protocols published by Bezemer et al [166] and Sohier et al [167] was used. A suspension
of Micrococcus lysodeikticus (Sigma, M3770) in water (2.3 mg/ml) was prepared, 100 µl
42
CHAPTER 2: RESULTS I: MICROPARTICLE FABRICATION
of which was added to 100 µl of release supernatant in a 96 well plate and the change in
turbidity at 37 ◦C over oneminutemeasured at 405 nmusing a colorimetric plate reader
(Infinite M200, Tecan Uk Ltd.). The change in turbidity of samples was compared to a
calibration plot in the linear range of 0-25 µg/ml to obtain the lysozyme concentration.
2.3.6 Selection of a Hydrogel to Position Microparticles
A number of hydrogels were assessed as the patterning substrate. Suitable gels had to
possess two key characteristics:
1. Physical characteristics that allowed positioning of microparticles without disrupt-
ing the structure of the gel (tearing) followed by rapid gelation to ensure the
positioned microparticles stay in place.
2. Chemical characteristics that facilitate the diffusion of large molecules such as
proteins with minimal binding or denaturation.
Both the physical and chemical characteristics also had to act together in a suitable way
to allow cell attachment, proliferation and differentiation.
A novel method to functionalise agarose with gelatin was selected. This provided a
substrate with the correct physical characteristics as well as the necessary cues for cell
adhesion and proliferation (Appendix D, Page 125).
This hydrogel facilitated positioning of microparticles with a high degree of accuracy
(Figure 2.16).
2.3.7 Micro-positioning of Microparticles
Microparticles were suspended in saline (0.9 %) and custom pulled glass capillaries
were used to inject and manipulate microparticles as desired. Glass capillaries were
coupled to a micro-injector (CellTran vario, Eppendorf ) to give precise control over
injection volumes. Accurate positioning was achieved using a micro-manipulator
(TransferMan NK2, Eppendorf ) and visualised with an inverted microscope (DM IRB,
Leica).
2.3.8 Statistical Comparisons and Data Analysis
Statistical analyses were carried out using the software environment ‘R’ [168, 169]
(version 2.10.1). Sample data was assessed for normality and variance using quantile-
quantile plots and F-tests, respectively. Statistical methods were chosen accordingly.
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Statistical significance was defined with a confidence interval of 95%. Comparisons
with a p-value of less than 0.05 were considered significant. For certain graphical com-
parisons box plots were favoured over bar graphs as they are better for representing
averages. Outliers (in normally distributed data) were defined as values that were ≥
2.5 quantiles from the mode.
All data analysis was carried out on an i486-pc-linux-gnu platform running Ubuntu
10.04 LTS. OpenOffice.org (version 3.2.0) and PythonTM (version 2.6) were utilised to
manage and process data.
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2.4 Results and Discussion
2.4.1 Fabrication
2.4.1.1 Polymer formulation
Two different formulations of PLGA were chosen for assessment. Specific details of
the formulations can be found in table 2.1 on page 39. These polymers were chosen
because they have similar characteristics but different lactide to glycolide ratios. PLGA
with a monomer ratio of 85:15 is known to have a slower degradation rate than 50:50
and both ratios have been documented for protein release [101, 170]. This difference in
degradation rates was exploited in order to influence protein release.
PLGA-PEG-PLGA was used as an adjunct in the polymeric formulation in order to
further modulate water ingress into the polymer matrix and allow further tuning of
release characteristics.
2.4.1.2 PLGA-PEG-PLGA Characterisation
Synthesis of PLGA-PEG-PLGA is susceptible to batch-to-batch variation and long-
term storage may lead to degradation and changes in polymeric characteristics. It
was important to characterise each batch after synthesis as well as at later time
points. Significant differences in the PLGA-PEG-PLGA structure could affect the
polymers overall hydrophilicity thus affecting water ingress, hydrolytic degradation
and protein release rates. Different overall chain length could also result in different
physicochemical characteristics.
The GPC and NMR data for different batches of PLGA-PEG-PLGA are shown (Ta-
ble 2.2). Each batch was assessed immediately after synthesis and at later intervals
to evaluate changes over time.
The batches show inter-batch variation but to no greater extent than intra-batch
variation. The discrepancies between batches appeared relatively small. Since no
data was available regarding manufacturing tolerances of this process with respect to
protein release it was decided that that this variation would be acceptable for initial
studies. Protein release from microparticles fabricated using different triblock batches
would be monitored for differences.
If we assume that hydrolytic degradation is the only breakdown method acting on
the copolymer then we would expect to see a reduction in PLGA chain length over
time and the ratios of monomers to remain the same. This reduction in chain length
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1HNMR GPC
Batch A MN %mole lactide % mole glycolide MN MW PDI
Mar 2011∗ 1577–1500–1577 83 17 2861 4590 1.60
Jun 2011 1706–1500–1706 71 29 2442 4022 1.65
Mar 2012 1695–1500–1695 75 25 2577 4539 1.76
Batch B
Jun 2011∗ 1589–1500–1589 72 28 1874 3338 1.78
Mar 2012 1435–1500–1435 73 27 2632 3844 1.46
Batch C
Jun 2011∗ 1428–1500–1428 70 30 2576 3960 1.54
Mar 2012 1653–1500–1653 75 25 3026 4582 1.51
Table 2.2: Proton NMR and GPC characterisation of PLGA-PEG-PLGA. Batches were
assessed post synthesis and at later intervals. This table details three batches
of copolymer; A, B and C. The dates indicate the date of assessment, the
first date (∗) being immediately after fabrication. The NMR MN is in the
format of the three polymer strings within PLGA-PEG-PLGA, the mass of
PEG being known and the PLGA chains determined numerically. Literature
commonly represents the data in this way.
would only be apparent in GPC data as it assesses complete chain lengths whereas
NMRworks under the assumption that all the monomers present are polymerised and
numerical averaging produces a result based on the assumption that the chain length is
monodisperse. It appears that there are polymer fragments and potentially un-reacted
monomers in the mixture. This is why the number average molecular weight value
differs between NMR and GPC techniques.
What we see from the data (Table 2.2) is that there appears to be no trend in the change
of PLGA-PEG-PLGA chain length over time. The results appear variable. We deduce
from this that the batch of polymer had a non-homogeneous bulk consistency so
aliquots used for analysis differed to a greater extent than any overall change induced
by degradation. This effect could potentially be mitigated in the future by the addition
of a final mixing step. Similarly there is a slight variation of the lactide:glycolide ratio
over time. This is also attributed to sampling variation.
2.4.1.3 Double emulsion microparticle fabrication
Microparticle fabrication within the group had previously been carried out using a
vortex mixer to form the primary emulsion [147, 171]. It was initially apparent that
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this method was variable as the degree of vortex achieved was dependent on the
technique of the user. A comparison was carried out between the vortex method
for emulsification and the use of a homogeniser which utilised a radial flow impeller
imparting shear stress.
Representative batches of microparticles were formed using vortex and homogeni-
sation methods. size distributions were assessed using laser diffraction (Figure
2.3).There is high degree of microparticle size variability exhibited my microparticles
formed using the vortex method. In contrast the homogenisation method produced
a more consistent size distribution. The size distribution of microparticles will
affect microparticle surface area thus diffusion and degradation rates. Some studies
exploit this releationship between surface area and drug diffusion rates to modulate
release [146]. In order to achieve consistent microparticle physical characteristics it was
decided that the homogenisation method would be utilised for all further fabrication.
Images of microparticles obtained using electron microscopy (Figure 2.4) show that
after fabrication and lyophilisation the microparticles retain a regular spherical mor-
phology. There are also few micro pores and no visible cracks in the microparticles.
These are factors that could affect protein release as the initial release is dependant
on protein release from, or near to, the surface of the microparticles. A greater
surface area resulting from a porous structure would likely have a higher burst
release. The SEM images qualitatively validate the sizing data obtained using laser
diffraction. Assessment of these formulations indicated that the inclusion of this
triblock copolymer has an influence on microparticle size. Increasing levels of PLGA-
PEG-PLGA, decrease the average microparticle size. It is likely that the copolymer
is stabilising the emulsion due to it’s surfactant structure. This would result in more
efficient emulsion generation and reduce the likelihood of micelles coalescing.
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Figure 2.3: Size distributions of microparticles formed using the vortex method and
the homogenisation method. Microparticles formed by vortex show
a higher variability in size to those formed using the homogenisation
method. Plots show the distribution of representative samples from three
independent batches of microparticles. Microparticles were fabricated
using the vortex method (2.3.3.1 on page 38) and the homogenisation
method (2.3.3.2 on page 38 – A and B speeds of 2,000 and 2,000 rmp) using
PLGA 50:50 (Table 2.1 on page 39) and sized using method 2.3.4.2 on page
41.
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Figure 2.4: Images of microparticles obtained using SEM alongside their correspond-
ing size distributions obtained using laser diffraction. Microparticles were
fabricated using the homogenisation method (2.3.3.2 on page 38 – A and
B speeds of 2,000 and 2,000 rmp) using PLGA 50:50 (Table 2.1 on page
39), sized using a laser diffraction method 2.3.4.2 on page 41 and imaged
using electron microscopy (2.3.4.1 on page 41). Microparticles contained
different amounts of PLGA-PEG-PLGA, in descending order; 0 %, 10%, 20
% and 30% (w/w)). 49
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Changing the homogenisation speed of the primary and secondary emulsions enabled
control of the resulting microparticle size (Figure 2.5). Additional factors such as
organic solvent volume and surfactant bath volume also affect the resulting size but
these and other variables were kept constant for this study. Two homogenisation
conditions were decided upon for further study. These yielded microparticles with
modal sizes of 21.7–26.2 µm and 73.0–88.0 µm.
Largermicroparticles in the 73–88 µm size range were taken forward for assessment for
use in the segmental defect. The smaller microparticles in the 22–26 µm size range were
briefly explored for their potential application in small mammal studies (Section ??,
Page ??). This smaller particle size is more conducive with injectable delivery into a
small site of interest.
2.4.1.4 Assessment of Protein Entrapment
Microparticles were fabricated in the 73.0 - 88.0 µm size range and HSA encapsulated
within them (1 % w/w). Polymer formulations consisted of both PLGA 50:50 and 85:15
with levels of PLGA-PEG-PLGA incorporation at 0 %, 10 % and 30 %. No significant
differences in encapsulation were observed between formulations (p=0.05). The mean
entrapment efficiency was 94 % with a standard deviation of 8.9 %.
Measurement of entrapment efficiency was a highly laborious process and pH varia-
tions could lead to errors. Since entrapment efficiency appeared to be independent of
polymer formulation, percentage protein release would be plotted based on loaded
protein rather than a measured value. This also facilitated the additional scale
showing the levels of actual protein release. This was considered more relevant
when determining a therapeutic effect of growth factor released from a fixed mass of
microparticles.
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Figure 2.5: Size distributions of two different representative batches of PLGA 50:50
(Table 2.1, page 39) microparticles formed using different homogenisation
protocols (method 2.3.3.2 on page 38 – A and B speeds of 2,000 & 2,000 and
4,000 & 9,000). Microparticles were sized using laser diffraction (method
2.3.4.2 on page 41). Batches of microparticles with modal sizes of 21.7 -
26.2 µm and 73.0 - 88.0 µm are shown. This shows how variations to the
protocol are able to vary the resulting size of microparticle batches.
51
CHAPTER 2: RESULTS I: MICROPARTICLE FABRICATION
2.4.2 Quantification of protein release
2.4.2.1 Formulation assessment
Initial release studies were carried out with a model protein; lysozyme. A model
protein was used because of the high cost of growth factors. Lysozyme was chosen
because it has similar physicochemical properties to BMP-2 (Table 2.3). It was hoped
that it would therefore be a good substitute for BMP-2 from a release standpoint. The
three growth factors of interest have basic isoelectric points (P I) so will all be positively
charged at physiological pH. Their molecular weights are relatively similar; although
VEGF may require an additional model protein with a higher molecular weight to
accurately mimic its release characteristics.
The activity of lysozyme can be assessed with a kinetic assay, this enabled us
to assess whether encapsulation and release was significantly detrimental the the
conformational activity of lysozyme. It also allowed us to differentiate lysozyme
release from HSA release. An overall protein loading of 1 % w/w was selected. It
exhibited high encapsulation efficiencies during previous assessment (Figure ??) and
would allow us to load growth factor at very high concentrations if necessary. Loaded
protein was a combination of active factor and HSA. Complementary levels of HSA
were used to achieve a 1 % w/w loading. In this case a 1:9 w/w ratio of lysozyme and
HSA were used as initial calculations suggested that this loading of growth factors
would be required in the segmental defect model to achieve therapeutic levels of
delivery.
Protein Molecular weight (kDa) Isoelectric point (P I)
HSA 66.5 5.3
Lysozyme 14.3 11.35
BMP-2 26 8.5
VEGF 38.2 8.5
PDGF 24.3 9.8
Table 2.3: Physicochemical characteristics of all proteins to be assessed within
microparticles in this thesis. The data was obtained from literature [172–
177].
In order to quickly identify achievable release profiles, a selection of formulations were
chosen. A PLGA-PEG-PLGA ratio of 30 % was the highest whereby the microparticles
still flowed at room temperature. Above this the microparticles tended to aggregate.
Ratios of 0 %, 10 % and 30 % (w/w) PLGA-PEG-PLGA were selected for each PLGA
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formulation. Cumulative protein release from these formulations can be seen in figures
2.6 and 2.7.By day 72 the microparticles had visibly degraded and protein was no
longer detected.
In order to correctly interpret this data it is important to have an understanding of
the underlying mechanisms that take place during degradation. A high initial release
in the first 12 to 24 hours (often termed ‘burst’ release) is due the detachment of
surface-bound protein and diffusion of protein near to the surface. A burst-type
release is only observed in PLGA 50:50 (30 % w/w PLGA-PEG-PLGA). As no other
formulations exhibit this burst, we hypothesised that the thorough washing protocol
during fabrication removed this surface-bound protein. The burst in this particular
formulation was attributed to physical polymer characteristics favouring water ingress
and facilitating a higher level of surface diffusion. PLGA 50:50 had a lower glass
transition (Tg) temperature than the corresponding 85:15 formulation [178]. Combining
this formulation with a high amount of PLGA-PEG-PLGA plasticiser will serve to
further modify its physical characteristics while increasing the hydrophilic component.
For this reason we deduced that the observed burst release could be attributed to
protein diffusion facilitated by water ingress.
A lag phase prior to protein release can be seen from PLGA 50:50 (0 %w/w PLGA-PEG-
PLGA) and PLGA 85:15 (10 %w/w PLGA-PEG-PLGA). A lag phase is generally thought
to be undesirable as release is often below therepeutically active levels. However in
certain situations this could be advantageous. For example if we want to mimic the
temporal expression of a particular growth factor (expressed after another) without
additional invasive procedures.
Formulations of particular interest are PLGA 50:50 (10 % w/w PLGA-PEG-PLGA) and
PLGA 85:15 (30 % w/w PLGA-PEG-PLGA) as these exhibit no burst release. They
instead immediately begin to steadily release protein at a consistent rate for a duration
of 7 and 25 days respectively. PLGA 85:15 (30 % w/w PLGA-PEG-PLGA) exhibited
almost perfect zero-order release over the first 7 days before tailing off (Figure 2.8).
This release occurred before the polymer had degraded since polymer was still present
at day 7. It was theorised that the release was instead due to swelling and diffusion
induced by the high level of PLGA-PEG-PLGA. Steady release over the initial 25 days
was exhibited by PLGA 50:50 (10 % w/w PLGA-PEG-PLGA) (Figure 2.9). This 25 day
release does not demonstrate perfect zero-order kinetics as the release appears to be a
combination of a mitigated burst release combined with degradationmediated release.
Addition of 10 % PLGA-PEG-PLGA allowed us to tune the release kinetics of PLGA
50:50 to provide a consistent protein release that could not be achieved with PLGA
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alone.
By day 30 all of the PLGA 50:50 microparticles had completely degraded and stopped
releasing protein but some of the 85:15 formulations continued releasing up to day 70.
Incomplete protein release was apparent in formulations releasing beyond two weeks.
It was speculated that this was partly due to a drop in pH induced by solubilised lactic
acid and glycolic acid. More regular buffer replenishment may have mitigated this
issue but the sampling/buffer-replenishment schedule was dictated by the levels of
protein release. As protein release reduced, the rate of sampling was reduced so that
the protein concentration was high enough to be within the linear working range of the
protein assay. The BCA assay relies on the reduction of Cu 2+ to Cu+ which proceeds
under alkaline conditions [136]. The drop in pH may have adversely affected this.
In addition this drop in pH most likely affected protein aggregation and adsorption.
A pH drop could lead to aggregation and reduced release of some proteins such as
albumin [111] or reduced adsorption of other proteins such as lysozyme [101]. It is
hypothesised that these factors are the main cause of incomplete release. Switching to
a more acid compliant protein assay such as the Bradford assay and using a higher
concentration of buffer salts are means by which we could have tackled this issue.
There appears to be no ideal release situation. Sometimes greater complete release
can be demonstrated in vitro under artificial conditions [101, 179] but these may not
be representative of in vivo performance. If great effort is made to try to maintain a
physiological pH, the requirements may have a detrimental affect on the proteins. For
example higher buffer salt concentrations would change the ionic strength and could
reduce polymer degradation or induce protein aggregation [180]. It was decided that
in order to keep release data comparable and applicable in vivo, future release studies
would be carried out under the same conditions.
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Figure 2.6: Cumulative release of HSA/Lysozyme from microparticles formulated
from 50:50 PLGA (Table 2.1 on page 39) with 30 % (), 10 % (N) and 0
% (•) w/w of PLGA-PEG-PLGA copolymer (Section 2.3.1). Protein release
was quantified using a BCA assay (Section 2.3.5.3). Error bars show ±
standard deviation of the mean; n=3.
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Figure 2.7: Cumulative release of HSA/Lysozyme from microparticles formulated
from 85:15 PLGA (Table 2.1 on page 39) with 30 % (), 10 % (N) and 0
% (•) w/w of PLGA-PEG-PLGA copolymer (Section 2.3.1). Protein release
was quantified using a BCA assay (Section 2.3.5.3). Error bars show ±
standard deviation of the mean; n=3.
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Figure 2.8: Cumulative release of HSA/Lysozyme from microparticles formulated
from 85:15 PLGA (Table 2.1 on page 39) with 30 % w/w of PLGA-PEG-
PLGA copolymer (Section 2.3.1). Protein release was quantified using a
BCA assay (Section 2.3.5.3). Error bars show ± standard deviation of the
mean; n=3.
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Figure 2.9: Cumulative release of HSA/Lysozyme from microparticles formulated
from 50:50 PLGA (Table 2.1 on page 39) with 10 % w/w of PLGA-PEG-
PLGA copolymer (Section 2.3.1). Protein release was quantified using a
BCA assay (Section 2.3.5.3). Error bars show ± standard deviation of the
mean; n=3.
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2.4.2.2 Biological activity of model protein
The significance of detecting only lysozyme is two-fold: Most importantly we can
verify that protein released at early and late time points is active and that the process
of fabrication and release from microparticles has not been detrimental. Secondly
we can differentiate the release of the model protein from the carrier protein (HSA).
This helped us to understand more complex issues regarding polymer degradation
mechanisms and how this can selectively discriminate the release of different proteins.
This is potentially an important factor when dealing with proteins with very different
physiochemical characteristics to the carrier protein.
The formulation that released protein over the shortest period (PLGA 50:50 (30 % w/w
PLGA–PEG–PLGA)) demonstrated a very close match between the expected release of
lysozyme and the measured activity of lysozyme. The expected release of lysozyme
was calculated based on the assumptions that 10 % of the total protein was lysozyme
and the proteins behave homogeneously. Table 2.4 shows how closely these values
correlate. This data indicates that for this fast releasing formulation, there are no
limiting factors that differentiate the proteins; they behave homogeneously. This shows
that the mechanism of release is independent of physiochemical characteristics that
differ between HSA and lysozyme.
Day Expected lysozyme (µg) Active lysozyme (µg)
1 57.0 ± 5.4 56.6 ± 14.1
2 12.8 ± 4.2 19.1 ± 4.7
3 4.1 ± 3.1 6.8 ± 3.9
4 0.6 ± 0.5 1.0 ± 0.6
5 0.4 ± 0.2 0.0 ± 0.9
Table 2.4: Active lysozyme release from PLGA 50:50 (Table 2.1) (30 % PLGA–PEG–
PLGA (Section 2.3.1)) measured using a kinetic activity assay (Section
2.3.5.4) compared with expected levels.
If, however we look at the release of lysozyme from formulations that offered a more
sustained release we don’t see this same correlation. The levels of released lysozyme
are higher at early points in the release window and trail off as the levels of lysozyme
are depleted (Table 2.5, Page 62). This suggests that the mechanism of release is
different and this mechanism exploits differences between Lysozyme and HSA to
differentiate them.
If the mechanism of release relied on diffusion through the micro–porous structure
of the polymer then we might expect to see this effect since the molecular weight
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of Lysozyme is a quarter that of HSA. Lysozyme could diffuse through this porous
network at a higher rate than HSA. This will likely be less of a pronounced issue for
the growth factors of interest because their molecular weights are all higher than that
of lysozyme.
Lysozyme is most active in the region of pH 6.2–9 [181] so as the PLGA degraded and
the pH dropped activity measurements became less sensitive. For the faster degrading
formulation PLGA 50:50, there were no successful Lysozyme detections beyond day
12. The actual pH levels of the release supernatants were determined (Figure 2.10). It
can be seen that day 12 is when PLGA 50:50 hydrolytic by-products cause a pH drop.
A similar correlation is seen with PLGA 85:15. The last successful lysozyme activity
determination was at day 26. As a result no comparisons between active lysozyme and
expected lysosyme were made beyond this point.
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Figure 2.10: Drop in pH induced by polymer microparticle degradation from PLGA
50:50 • and PLGA 85:15 N. This is not likely to be representative of
the situation in vivo because fluids will be continually replenished and
metabolic pathways will process the acidicmonomers. Error bars indicate
± standard deviation; n=6.
61
CHAPTER 2: RESULTS I: MICROPARTICLE FABRICATION
Microparticle polymer formulation: PLGA 50:50 (10 % (w/w) PLGA–PEG–PLGA)
Day Expected lysozyme (µg) Active lysozyme (µg)
1 3.0 ± 1.2 24.0 ± 4.3
2 3.1 ± 0.4 5.6 ± 1.0
3 4.5 ± 0.6 11.4 ± 1.8
4 3.9 ± 1.4 9.4 ± 1.7
5 1.6 ± 0.3 7.9 ± 0.7
6 2.3 ± 0.7 6.8 ± 1.8
7 1.1 ± 0.2 3.0 ± 0.9
Microparticle polymer formulation: PLGA 8515 (30 % (w/w) PLGA–PEG–PLGA)
Day Expected lysozyme (µg) Active lysozyme (µg)
1 9.6 ± 1.5 26.6 ± 0.8
2 8.2 ± 0.5 18.0 ± 0.1
3 10.9 ± 0.5 17.3 ± 1.1
4 10.5 ± 2.4 15.7 ± 0.9
5 12.2 ± 2.4 15.7 ± 2.1
6 15.7 ± 5.0 2.7 ± 2.7
7 4.9 ± 1.3 1.7 ± 0.4
Microparticle polymer formulation: PLGA 8515 (10 % (w/w) PLGA–PEG–PLGA)
Day Expected lysozyme (µg) Active lysozyme (µg)
13 0.4 ± 0.1 1.6 ± 0.9
18 7.3 ± 1.5 19.2 ± 3.0
21 8.3 ± 2.4 23.9 ± 3.5
26 1.8 ± 0.5 7.9 ± 2.0
29 1.0 ± 0.3 0.0 ± 0.0
Table 2.5: Lysozyme release precedes that of the albumin carrier. Active lysozyme
was measured using a kinetic activity assay (Method 2.3.5.4) and compared
with expected levels as arithmetically determined from total protein release
(Method 2.3.5.3).
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2.4.2.3 Robustness
For thismicroparticle system to be a robust platform technology it was essential that the
results were repeatable. A small repeatability study was carried out with formulations
of interest. Three independent operators each fabricated a batch ofmicroparticles of the
same formulation following a standard operating procedure. The protein release from
each sample was assessed (Figures 2.11 and 2.12). Although some variability can be
seen, the shape of the release profiles remained distinct between different formulations.
All samples from PLGA 50:50 (10 % (w/w) PLGA-PEG-PLGA) released until day
30 (Figure 2.11) and all samples from PLGA 85:15 (30 % (w/w) PLGA-PEG-PLGA)
released up to day 10 (Figure 2.12).
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Figure 2.11: Cumulative release of HSA/Lysozyme from microparticles formulated
from 50:50 PLGA (Table 2.1) with 10 % w/w of PLGA-PEG-PLGA
copolymer (Section 2.3.1). Protein release was quantified using a BCA
assay (Section 2.3.5.3). Plots show protein release from three batches each
released in triplicate. Error bars show ± standard deviation of the mean;
n=3.
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Figure 2.12: Cumulative release of HSA/Lysozyme from microparticles formulated
from 85:15 PLGA (Table 2.1) with 10 % w/w of PLGA-PEG-PLGA
copolymer (Section 2.3.1). Plots show protein release from three batches
each released in triplicate. Protein release was quantified using a BCA
assay (Section 2.3.5.3). Error bars show± standard deviation of the mean;
n=3.
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2.4.2.4 Blending formulations
Another method to tailor release profiles (besides changing the individual formula-
tions) would be to blend mixtures of microparticles from two differently formulated
populations. A small study was carried out to assess The effect of blending. The
formulations PLGA 50:50 10 % and 30 % w/w PLGA-PEG-PLGA exhibited very
different protein release profiles (Figure 2.6, Page 55). One released over 3 days,
the other released over 30 days. It was hypothesised that a 1:1 w/w blend of these
formulations would produce an intermediate level of release resulting in a high initial
burst release followed by a sustained release. A formulation of PLGA 50:50 (20 % (w/w)
PLGA-PEG-PLGA) was also assessed to see how this would compare to the blend.
The release profiles confirmed the hypothesis that an intermediate release profile can be
attained by blending different formulations of microparticles (Figure 2.13). The blend
exhibits the high initial release over the first two days as seen in the 30 % PLGA-PEG-
PLGA formulation but also sustains protein release up to day 20. This kind of release
profile may be useful for a therapeutic entity that has to quickly attain therapeutic
levels then sustain these levels.
It should be noted that although some formulations appear to release more that 100 %
of encapsulated protein this is simply an artefact of the way that total protein is
calculated. This method makes the assumption that the protein encapsulation within
the polymer microparticles is homogeneous. Release studies are carried out on a
sample of microparticles and some samples appear to have higher levels of protein
than the numerically calculated average.
A comparison of protein release from the blended formulation with the equivalent
single formulation was carried out (Figure 2.14). These release profiles appear similar.
They both exhibit high initial release followed by a more sustained release. This
indicates that blending of formulations is not necessary to achieve this kind of release
profile but a blending method can be used to simulate formulations that have not been
fabricated.
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Figure 2.13: Cumulative release of HSA/lysozyme from microparticles formulated
from PLGA 50:50 (Table 2.1) with 10 % (N) and 30 % () w/w PLGA-
PEG-PLGA (Section 2.3.1) comparedwith HSA/lysozyme release from an
equal mixture of the two formulations (△). Protein release was quantified
using a BCA assay (Section 2.3.5.3). Error bars show± standard deviation
of the mean; n=6.
67
CHAPTER 2: RESULTS I: MICROPARTICLE FABRICATION
Figure 2.14: Cumulative release of HSA/Lysozyme from microparticles formulated
from PLGA 50:50 (Table 2.1) with 20 % () w/w PLGA-PEG-PLGA
(Section 2.3.1) compared with the blended formulation (△) detailed
in figure 2.13. Protein release was quantified using a BCA assay
(Section 2.3.5.3). Error bars show ± standard deviation of the mean; n=6.
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2.4.2.5 Applicability of the model protein
Formulations of interest were identified with lysozyme as a model protein. Sustained
release formulations were identified and repeatability determined. A comparison
between lysozyme and BMP-2was required to ensure that similar release profiles could
be generated.
A formulation of PLGA 50:50 (10 % (w/w) PLGA-PEG-PLGA) had been of particular
interest (Figures 2.6, 2.11 and 2.13) due to the low level burst release and sustained
duration of release. This was hypothesised as being a desirable characteristic for the
release of BMP-2 in a segmental defect.
Two batches of microparticles were fabricated using this formulation. One contained
the typical HSA/lysozyme protein loading and the other substituted lysozyme with
BMP–2. Total protein release was assessed using BCA substrate.
These two batches showed similar release profiles (Figure 2.15). They both exhibit
a small step at day 20 which is most likely a result of switching between different
mechanisms of release: The point at which diffusion mediated release begins to tail
off and bulk erosion of the polymer begins to mediate the majority of protein release.
The release from both batches ended during the period of day 30-40.
This study indicates that the release profiles obtained using model proteins are
applicable to other factors with similar physiochemical properties. Specifically the
profiles obtained using lysozyme appear to be applicable to BMP–2.
It would have been advantageous to assess the release of BMP–2 using a protein
specific method and compare this to the release of lysozyme only. Since these actives
make up only 10 % of the total protein, subtle differences may have been masked by
HSA release. Unfortunately Assessment of released BMP–2 using an enzyme-linked
immunosorbent assay (ELISA) was inconclusive and indicated BMP–2 levels lower
than anticipated. This was further explored in Chapter 3.
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Figure 2.15: The release profile of model protein/HSA matches the release of BMP–
2/HSA. This indicates that Lysozyme was a good model. Cumulative
protein release from two batches of microparticles of an identical
formulation; one containing lysozyme/HSA (N) and the other containing
BMP–2/HSA (). The polymer formulation was PLGA 50:50 (Table 2.1)
(10 % (w/w) PLGA-PEG-PLGA (Section 2.3.1)). For clarity, error bars
indicate ± standard deviation of the mean; n=3.
70
CHAPTER 2: RESULTS I: MICROPARTICLE FABRICATION
2.4.3 Micro-positioning of Microparticles
This is a brief introduction to a process with the potential to generate growth factor
gradients. The aim was to accurately position microparticles within a hydrogel with a
positioning accuracy in the order of hundreds of microns.
In order to produce accurate and complex growth factor gradients on a small scale, for
research purposes, it was desirable to positionmicroparticles accurately with a high de-
gree of precision. The paradigm that was selected was the use of a micro-manipulator
in conjunction with a micro-injector. This facilitated the accurate placement of a needle
followed by accurate deployment of a microparticle suspension. In practice this was
a little more complex. Due to forces such as hydrophobic interactions and surface
tension on these small scales, microparticles required ‘nudging’ from a smaller needle
to achieve precise placement.
Using the methods selected A degree of precision in the order of hundreds of microns
was achieved (Figure 2.16). This would facilitate the potential generation of gradients
able to influence individual mammalian cells on a monolayer. Using time-lapse
imaging or immunohistochemistry techniques the effects of individual growth factors
or even complex mixtures could be assessed.
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Figure 2.16: Microparticles positioned in 1 % agarose-gelatin hydrogel (Method 2.3.6
on Page 43) using a micro-manipulator and micro-injector (Method 2.3.7
on Page 43). These images demonstrate the greatest degree of positional
accuracy that can be achieved with these therapeutic microparticles.
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2.5 Conclusions
A comparison between emulsification methods between vortex agitation and the use
of a homogeniser led to a method of fabrication with consistent microparticle size dis-
tributions. The microparticles exhibited regular spherical morphologies with minimal
pores or defects. Comparisons between operators indicated a high degree of robustness
of the fabrication protocol. Increasing levels of PEGwithin the polymer formulation led
to a smaller average distribution of microparticles although all assessed formulations
were within acceptable tolerances. It was hypothesised that the triblock copolymer
increased the emulsion stability leading to the smaller size distribution.
A high entrapment efficiency was exhibited for all formulations. Entrapment efficiency
was independent of microparticle formulation. The inclusion of a high level of
HSA and short emulsion steps appear to have acted as expected in producing high
entrapment efficiencies but comparisons would have to be carried out to be sure.
Lysozyme was identified as a model protein and release studies assessing the release
of total protein identified that different microparticle formulations exhibited different
protein release profiles. The release profiles released protein over as little as 2 days to
as long as 30 days (with consistent release). It appears that the inclusion of the triblock
copolymer enabled stable protein release before the PLGA began to degrade.
Issues of incomplete protein release were identified for longer-releasing formula-
tions. It was speculated that this incomplete release was due to protein aggre-
gations/adsorption. This was potentially caused by acidic degradation products.
Acidic environments were identified in release samples. Degradation in vivo would,
of course, be different and these acidic products would be metabolised. It was
speculated that although incomplete issues were identified, the actual release profiles
were representative of the likely in vivo release.
The biological activity of released lysozyme was confirmed up to day 26. Beyond this,
acidity within the samples prevented accurate analysis.
The protein release from BMP-2/HSA loaded microparticles was found to be highly
comparable to the release of lysozyme/HSA. This indicates that the methods de-
veloped here could lead to similar release from other growth factors with similar
physicochemical characteristics.
A method to utilise the fabricated microparticles was briefly assessed involving
positioning the microparticles within a hydrogel with a high degree of positional
accuracy. Positional accuracy of hundreds of microns could be achieved using this
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method. This makes it suitable for the study of individual cell interactions in a
monolayer environment. To achieve a greater degree of accuracy, different techniques
such as optical tweezers would be required.
The aim of this chapter was to verify the release of protein from PLGA-based
microparticles in preparation for a segmental defect model. The ability to control the
release rate of protein was verified as well as the release of an active model protein.
Methods to validate batches ofmicroparticles have been explored andwill prove useful
for the assessment of potential experimental batches.
2.6 Future Work
The issues of incomplete release should be further addressed. Incomplete protein
release from PLGA microparticles is a well known issue [137] and a number of
important reviews have been published on the subject. If the particular issues here
can be elucidated and mitigated in an in vivo environment then this could lower the
growth factor requirements of potential therapeutics.
The activity of released lysozyme was verified. The next important steps are to verify
the activity of released growth factors. Once the activity of a growth factor can be
verified, this system can be prepared for for its main application in vivo.
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Results II: Bioactivity Assessment of
Encapsulated BMP-2
3.1 Introduction
In Chapter 2 some of the potential causes of protein denaturation resulting from
entrapment and release from a polymeric system were introduced. One of the
main causes is the water/oil interface present during emulsification. Procedures
were implemented to specifically address this. These included an albumin carrier to
competitively block the interface and a processing method that minimised interface
exposure time. The release of active lysozyme was verified showing that active protein
release was possible.
Encapsulated proteins would still be exposed to physiological temperature and, once
the polymer hydrates, water and a physiological ionic strength. A pH drop within the
polymer is still thought to occur. The interior of the polymer structures would initially
be at physiological pH but as the polymer degrades this would become more acidic.
This pH drop may cause aggregation and adsorption of growth factors. As the pH
continues to drop the risk of acid-catalysed hydrolysis increases.
A pH drop will be more of an issue in long-term formulations such as the one required
for BMP-2 release. It was seen as a priority to assess the activity of this potentially
challenging formulation.
Assessment of BMP-2 in vitro was carried out to test whether the BMP-2 was active in
sufficient quantity to elicit a biological response. This was a crucial step that dictated
whether the proposed in vivo models could go ahead based on current encapsulation
protocols. Problems would require the process to be re-assessed and modified.
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Assessment involved measuring the effect of released BMP-2 on a cell monolayer.
There are twoways to approach this. Onemethod involves carrying out a release study,
sampling the media at various time points and then culturing cells with this media.
This method had practical limitations. If denaturation is observed it may have occurred
after release but before culture on cells. This would give a false negative result. The
selection of a buffered solution to release into would also have been difficult. Previous
studies used PBS but cells require culture media. If PBS was mixed with culture media
after release, concentrations of BMP-2 may have been too low to detect. Lyophilisation
then re-suspension of the protein solution would have left phosphate salts, potentially
denaturing the growth factor. Release into cell culture media was an option but this
renders protein assays useless because of all of the native protein in culture media.
Without a protein assay there was no way to assess whether cell culture media affects
the protein release rate. The issues of post-release denaturation are still also present
and risks of bacterial/fungal infection during sampling are increased.
The other method to assess released BMP-2 activity is to assess the effect of cells
cultured directly with microparticles. The inherent limitation here is that there is no
way to know if a biological effect is from initially released BMP-2 and whether later-
released BMP-2 is still active and inducing a continued biological effect. Additional
controls are required in this kind of set-up to ensure that biological changes are a result
of released BMP-2 and not just the presence of the microparticles. This method was
selected because it more accurately mimics the intended in vivo application.
Bone Morphogenetic Protein-2 (BMP-2) induces bone formation and plays an impor-
tant role in osteoblast formation through the differentiation of pre-osteoblasts [182]
and mesenchimal stem cells [183]. Differentiation can be measured in a number of
ways, generally early up-regulation of alkaline phosphatase (ALP) is assessed. Up-
regulation of ALP is usually associated with differentiation but can also be non-
specifically expressed so this is usually measured in conjunction with other indications.
Bone-like mineralised matrix is a strong indication of osteoblasts. This is generally
stained for and assessed qualitatively. A later marker, osteocalcin can also be measured
as higher levels are linked with osteoblast production [182].
A murine calvarial osteoblast cell line (MC3T3-E1) was selected for this differentiation
study. Cell lines are generally easier to culture than primary cells and high numbers
of cells can be easily generated. This cell line responds to BMP-2 by expressing
higher levels of ALP and producing mineralised matrix [184, 185]. Mineral deposition
is usually homogeneous and obvious which is useful for a qualitative subjective
assessment.
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Quantification of BMP-2 was carried out using a different cell line. A murine myoblast
cell line (C2C12) was selected. This is because C2C12 cells respond to BMP-2 in a
proportional way [186, 187]. Expression of ALP correlates to BMP-2 concentrations
in culture media. This means that by measuring ALP concentrations, active BMP-
2 concentrations can be determined. This cell line was not used for co-culture and
differentiation because there is very little literature regarding terminal differntiation
of C2C12 cells into osteoblast-like cells, specifically matrix mineralisation. It has
been suggested that mineral deposition from C2C12 cells can be inhomogeneous and
difficult to assess.
3.2 Aims
The purpose of this set of experiments was to test whether the released BMP-2 was
active and able to induce a biological effect. The nature of this longer-releasing
formulationmeans that a proportion of protein release is mediated by bulk degradation
of the polymer. This exposes the encapsulated protein to less favourable micro-
environments.
This chapter aims to show that a polymer formulation providing a gradual and
prolonged release of BMP-2 is able to induce a biological effect in vitro. This
formulation exhibits a very small burst release so any biological response will most
likely have been induced by BMP-2 released after the first day or two.
The activity of BMP-2 batches were assessed in preparation for in vivo work. The
non-commercial source of rhBMP-2 and previous issues of detection using an ELISA
necessitated this verification.
3.3 Methods
3.3.1 Microparticle Fabrication
Microparticles were fabricated from PLGA 85:15 (10 % (w/w) PLGA-PEG-PLGA) in the
larger size range (Section 2.3.3.2, Page 38). Protein loading was analogous to initial
lysozyme studies (0.1 % (w/w) BMP-2 and 0.9 % (w/w) HSA). Control microparticles
were loaded with HSA alone.
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3.3.2 Microparticle Sterilisation
Microparticles were sterilised for cell culture using ultravoilet irradiation. Briefly,
microparticles were placed in a Class 2 biological safety cabinet (Contamination control
laboratories, 5001-1-LH) and exposed to an ultraviolet sterilisation cycle for 20 minutes.
The particles were then agitated and exposed for a second cycle. This is a common
method of sterilising polymeric biomaterials for cell culture [188].
3.3.3 Growth Factor Batches
Recombinant human BMP-2 was obtained from Walter Sebald (University of Wurzburg,
Germany). All BMP-2 documented in this thesis was obtained from this source. The
BMP-2 was obtained in three batches:
1. June, 2010.
2. September, 2010.
3. Febuary, 2011.
Batches of BMP-2 will from here on be referred to as 1, 2 and 3. Batch 1 was used for
microparticle encapsulation and release within this chapter and batch three was used
for biological quantification method development. Batch 2 was supplied in greater
quantity and was set aside for use in the segmental defect in vivo study.
3.3.4 Cell Culture
3.3.4.1 Subculturing of murine preosteoblast derived cells (MC3T3-E1)
Initial MC3T3-E1 work was carried out using a cell line provided by B. Hoflack (Dres-
den, Germany) and subcultured at the Institute of Health and Biomedical Innovation
(IHBI) (Queensland University of Technology, Brisbane, Australia). Later work, carried out
in the UK, utilised a cell line obtained from LGC Standards. Subculturing and ex-
pansion was carried out using α Minimum Essential Medium (αMEM) supplemented
with 10% v/v Foetal Bovine Serum and Penicillin/Streptomycin at a concentration of
50 U/ml and 50 µg/ml respectively. Cells were maintained at 37 ◦C with 5% CO2 in a
humidified atmosphere.
Osteogenic cell differentiationwas inducedwith the addition of 10mM β-glycerophosphate,
0.1 mM ascorbate-2-phosphate and 100 nM dexamethasone to the aforementioned
expansion media. Cells were cultured in this media for the duration of differentiation.
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3.3.4.2 Subculturing of murine myoblast derived cells (C2C12)
This cell line was obtained from LGC Standards. Subculturing and expansion was
carried out using Dulbecco‘s Modified Eagle Medium (DMEM) supplemented with
10% v/v Foetal Bovine Serum, Penicillin/Streptomycin at a concentration of 50 U/ml
and 50 µg/ml respectively and L-glutamine at a concentration of 2mM. Cells were
maintained at 37 ◦C with 5% CO2 in a humidified atmosphere.
3.3.4.3 Cell passaging
Cells were washed using PBS and incubated with a small volume of trypsin (0.25
%)/EDTA (0.02 %) for approximately 4 minutes, until cells visibly detached. Trypsin
was deactivated by adding an equal volume of complete media. The cell suspension
was centrifuged at 180 g for 5 minutes. The supernatant was aspirated, the cells
re-suspended and added to fresh flasks. Cells were never cultured beyond 80 %
confluency and a split ratio of 1 in 6 to 1 in 12 was used depending on the cells and
rate of growth.
3.3.4.4 Cell counting
Cells were counted using a heamocytometer. Cell counting ensured that consistent
seeding densities were achieved during passaging and assays. A suspension of cells
was introduced into a haemocytometer, cells within a specific volume were counted
using phase contrast microscopy and multiplied by the volume to obtain a number of
cells per millilitre.
3.3.4.5 Staining for mineral deposition
Alizarin red S was prepared at a concentration of 20 mg/ml in deionised water. The
pH was adjusted using ammonium hydroxide (0.5 M) solution until the alizarin red
solution was in the pH range 4.1 – 4.3. The cell monolayer was washed with PBS and
fixed with ice cold methanol. Alizarin red solution was added to the cell monolayer
which was incubated at 37 ◦C for 5 minutes. Deionised water was used to wash away
excess stain and the cell layer was immediately imaged.
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3.3.4.6 Alkaline phosphatase detection and quantification
To determine alkaline phosphatase levels a p-nitrophenyl phosphate (pNPP) solution is
used. Alkaline phosphatase dephosphorylates pNPP to produce p-nitrophenyl (pNP).
This is a yellow molecule with strong absorbance at 405 nm that can be quantified
colorimetrically. The levels of pNP correlate with the levels of alkaline phosphatase.
A cell lysis buffer was prepared by adding 0.1% Triton
TM
X-100 to 0.2 M tris buffer.
The cell monolayer was washed with PBS then incubated with this cell lysis buffer at
−20 ◦C. The resulting cell lysate was centrifuged at 10,000 rpm for 10 minutes at a
temperature of 4 ◦C. The resulting supernatant was mixed in equal parts with buffered
p-nitrophenyl phosphate solution, incubated in darkness at room temperature for 30
minutes. The absorbency at 405 nm was measured. Negative controls (lysis buffer –
no cells) were subtracted from data and results were compared to a calibration plot to
determine specific alkaline phosphatase levels.
3.3.4.7 Experimental groups
Two different amounts of microparticles (control and BMP-2-loaded) were cultured
in 48-well tissue culture treated plates along with MC3T3-E1 cells. Indications of
differentiation were assessed at three time points (10, 17 and 24 days). Experimental
groups are defined in table 3.1. Appropriate control groups were included to avoid
potential false positive results induced by the microparticle system.
Group Description
1.mp.low BMP-2 loaded microparticles (0.5 mg/well)
2.mp.high BMP-2 loaded microparticles (5 mg/well)
3.ostegenic Osteogenically supplemented media (Section 3.3.4.1, Page 78)
4.control Control cells; no additional treatment
5.mp.low.control HSA loaded microparticles (0.5 mg/well)
6.mp.high.control HSA loaded microparticles (5 mg/well)
Table 3.1: Experimental groups for co-culture of microparticles with a murine
calvarial osteoblast cell line (MC3T3-E1)
3.3.5 Statistical comparisons and data analysis
Statistical analyses were carried out using the software environment ‘R’ [168, 169]
(version 2.10.1). Sample data was assessed for normality and variance using quantile-
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quantile plots and F-tests, respectively. Statistical methods were chosen accordingly.
Statistical significance was defined with a confidence interval of 95%. Comparisons
with a p-value of less than 0.05 were considered significant. For certain graphical com-
parisons box plots were favoured over bar graphs as they are better for representing
averages. Outliers (in normally distributed data) were defined as values that were ≥
2.5 quantiles from the mode.
All data analysis was carried out on an i486-pc-linux-gnu platform running Ubuntu
10.04 LTS. OpenOffice.org (version 3.2.0) and PythonTM (version 2.6) were utilised to
manage and process data.
Pairwise statistical comparisonswere carried out using aWelch t-test. This was selected
because unequal variance was observed between groups. Full results of statistical
comparisons can be found in Appendix F.
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3.4 Results and Discussion
3.4.1 Protein release from a sustained release microparticle formulation
This study was carried out in parallel with initial release studies before all the release
data was available. It was initially speculated (based on the results of a previous
PhD student; Andrew Olaye [189]) that a polymer formulation of PLGA 85:15 (10
% (w/w) PLGA-PEG-PLGA) would be suitable for a sustained duration of release.
This formulation was later dropped in favour of a faster-releasing more sustained
formulation.
The microparticle sizes were verified to have a mean size of 97.9 µm and lower
and upper quartiles of 79.1 and 118.9 µm respectively. Electron microscopy images
indicated a regular spherical morphology.
A short protein release studywas carried out to verify themicroparticles were releasing
protein. Sustained protein release for the full duration of the 2 week study was
demonstrated (Figure 3.1).
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Figure 3.1: Cumulative release of HSA/BMP-2 from microparticles formulated from
85:15 PLGA (Table 2.1) with 10 % w/w of PLGA-PEG-PLGA copolymer
(Section 2.3.1). A steady release rate of protein is seen over the two week
duration. Protein was quantified using a BCA assay (Section 2.3.5.3). Error
bars show standard deviation of the mean; n=9.
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3.4.2 Effect of released BMP-2 on cells – ALP response
Alkaline phosphatase (ALP) is a hydrolase enzyme, the cellular expression of which is
enhanced at the early stages of osteogenic differentiation. It can be used (in conjunction
with other methods) to determine whether osteogenic differentiation is occurring.
ALP expression was quantified at three experimental time points. The period of ALP
expression as well as the levels varies between cell types and culture conditions. Since
no data was available for the sustained release of BMP-2 in this way and its effect on
MC3T3-E1 cells, the time points chosen were estimations.
Expression of ALP from groups cultured with microparticles exhibited a higher
standard deviation in some cases. This could have been due to differences in the
amounts of microparticles or non-homogeneous protein encapsulation within the
microparticles causing varying effects. This is something that would require further
investigation. If non-homogeneous protein encapsulation occurs, this would have
a more significant effect when looking at smaller populations or even individual
microparticles.
At day 10 (Figure 3.2), no significant difference was observed between osteogenically
supplemented media and a low amount of microparticles. Comparisons between
all other groups indicated significant differences. The control group expressed the
lowest level of ALP. The higher amount of BMP-2 loaded microparticles resulted in
the highest expression of ALP (p<0.001). This indicated that active BMP-2 is inducing
differentiation. Furthermore, it indicated a dose dependant response. The lower
amount of microparticles did not induce the same level of ALP expression (on day
10) as the higher amount, they instead have an effect analogous to osteogenically
supplemented media.
A similar trend was seen on days 17 and 24 (Figure 3.3). On both days there
was no significant difference in ALP expression between a high level of BMP-2
loaded microparticles and osteogenically supplemented media. On day 17 all groups
expressed significantly higher levels of ALP than the control group.
Further analysis at different time points would have been illuminating as ALP
expression could have beenmore gradual from the osteogenically supplementedmedia
group in comparison to BMP-2-releasing microparticles.
The important result from this study is that the BMP-2 loaded microparticles induce a
greater than (or equal to) level of ALP expression to osteogenic supplements at all time
points and a greater level of ALP than control groups at all time points.
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Figure 3.2: Boxplot showing the level of alkaline phosphatase (ALP) expressed at
day 10 of culture with MC3T3 cells. ALP was quantified through
dephosphorylation of pNPP to form pNP (Section 3.3.4.6). All groups
express significantly more ALP than the control. A large amount of BMP-2
releasing microparticles (2.mp.high) had the highest effect (p<0.001).
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Figure 3.3: Boxplots showing the level of alkaline phosphatase (ALP) expression at
day 17 (left) and 24 (right) of culture with MC3T3 cells. A higher amount
of BMP-2 releasing microparticles (2.mp.high) causes the expression of
significantly more ALP than control groups at both time points. Effects at
these timepoints are less significant than at day 10 because ALP is known
to be expressed at early stages during osteogenic differentiation.
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3.4.3 Effect of released BMP-2 on cells – Mineral deposition
Alizarin red is used to qualitatively assess mineral deposition histologically as it
strongly binds to the calcium in mineralised matrix. Mineral deposition was assessed
because it a more difinitive indication of osteogenic differentiation than ALP. Mineral
deposition is analogous to early bone formation.
Both amounts of BMP-2 releasing microparticles showed mineral deposition at all
measured time points in contrast to control microparticles which show no mineral
deposition (Figure 3.4). By day 24, osteogenically supplemented media samples
formed mineralised nodules typically seen with MC3T3-E1 cells. The mineralised
nodules formed in the presence of BMP-2 releasing microparticles had a different
appearance. They were smaller and more homogeneous across the well. Optical
microscopy images of the nodules indicated that they formed a uniform distance from
the microparticles and followed the contours of the microparticles (Figure 3.5). This
indicates a potential concentration or gradient effect. Mineral deposition stained in the
presence ofmicroparticles turned from red to yellow over time. This is why themineral
deposition in Figure 3.5 appears slightly yellow. ALizarin red stain turns yellow under
acidic conditions. It was hypothesised that residual acidic monomers present from
hydrolytic breakdown on the polymer induced this change.
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Day 10 Day 17 Day 24
1.mp.low
2.mp.high
3.osteogenic
4.control
5.mp.low.control
6.mp.high.control
Figure 3.4: Representative images showing mineral deposition from a murine
calvarial osteoblast cell line visalised using alizarin red. Labels indicate
experimental groups and time points. See Table 3.1 on Page 80 for full
details of experimental groups. The important observation to note here
is that the BMP-2 microparticle group and the osteogenic positive control
group both show indications of bone-like mineral deposition.
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1.mp.low
3.osteogenic
4.control
5.mp.low.control
Figure 3.5: Mineral deposition from a murine calvarial osteoblast cell line (MC3T3-
E1). Images of MC3T3 cells with microparticles were taken after 10 days of
culture and control images were taken on day 24. This is because only at
this time point did the osteogenically supplemented control group exhibit
mineral deposition. Mineral deposition was stained with alizarin red and
images were obtained using phase contrast optical microscopy.
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3.4.4 Quantification of released BMP-2 using an ELISA
Activity of released BMP-2 was established. A quantitative analysis was the next step.
This would determine the level of BMP-2 (if any) that was becoming denatured and
enable us to better estimate the amount of microparticles that would be required to
elicit an appropriate biological response in vivo.
Samples from the verification release study (Figure 3.1, Page 83) were assessed using an
enzyme-linked immunosorbent assay (ELISA). This method detects molecules based
on a specific binding site. The assumption is generally made that any small molecules
able to bind to this site are structurally undamaged, so active.
The ELISA was supplied with a small quantity of BMP-2 reference standard for
calibration plots. Due to the convenient small aliquot of the reference standard this was
used for a calibration plot rather than the batch of BMP-2 used in the microparticles.
This decision was mainly based on practicality. Reconstituting a larger BMP-2 aliquot
from the original batch was seen as unnecessary as different sources of BMP-2 should
have similar activity levels
The ELISA produced a good calibration plot but samples of release supernatant
exhibited a lower activity than expected (although still within the linear working
range of the assay). A comparison between expected BMP-2 values (based on total
protein quantification) and measured values (measured using ELISA) highlights this
discrepancy (Table 3.2).
Day Predicted (µg) Measured (µg)
0.25 7.12 1.32
1 8.86 1.67
2 11.72 1.84
3 14.16 1.99
4 18.56 2.11
6 26.18 2.20
7 29.46 2.25
9 34.06 2.50
10 37.95 2.63
13 40.93 2.84
Table 3.2: Predicted cumulative amount of BMP-2 release based on total protein
release from microparticles compared with measured levels of BMP-2
release (as quantified using an ELISA). Levels of BMP-2 were lower than
expected.
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The values determined using the ELISA were up to 20 times lower than expected. This
effect could have been caused by three circumstances:
1. The BMP-2 was becoming denatured as a result of encapsulation / release.
2. The experimental batch of BMP-2 was of a lower activity than the reference
standard.
3. The ELISA was not detecting the experimental batch of BMP-2 correctly.
Due to limited samples it was not possible to fully explore these circumstances. It was
decided that a biological method for quantification was more desirable. A quantifiable
biological response was explored to determine the cause of these low activity readings.
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3.4.5 Quantification of BMP-2 batches using a cell line
A proportional expression of ALP (in response to BMP-2) was verified (Figure 3.6).
This response indicates a limit of detection between 0 and 100 ng/ml and a saturation
point beyond 1000 ng/ml. This linear expression is not novel but it was important
that protocols be developed and verified for this method so that it could be used as an
analytical tool.
The BMP-2 was supplied from a non-commercial source, as a result there was no
certificate of analysis. The lack of any reference standard meant that only relative
comparisons between batches were possible. Batch 3 exhibited a biological response
within anticipated concentrations (Figure 3.6) [187]. This indicated that this batch is
active within an expected range. Batch 1 was encapsulated within the microparticles
and assessed with the ELISA, it demonstrated lower activity (Table 3.2).
The three batches of BMP-2 were assessed. Assuming they had identical activity, the
biological effect exhibited by C2C12 cells would have been the same.
Comparison of the biological activity between the three BMP-2 batches showed that
batch 1 had significantly lower activity than the other two batches (Figure 3.7). Batches
2 and 3 have more similar (though statistically different) levels of activity. The lower
than expected activity of batch 1 shows that this was a contributing factor to the lower
than expected detection in the ELISA. Subsequent work used the more active batches
2 and 3.
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Figure 3.6: Expression of alkaline phosphatase (ALP) from C2C12 cells in response
to different concentrations of BMP-2. ALP was quantified through
its enzymatic dephosphorylation of para-nitrophenylphosphate to para-
nitrophenol (Section 3.3.4.6). Para-nitrophenol was quantified colorimetri-
cally. Error bars indicate ± standard deviation; n=6.
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Figure 3.7: Expression of alkaline phosphatase (ALP) from C2C12 cells in response
to an identical concentration of BMP-2 from three different batches.
ALP was quantified through its enzymatic dephosphorylation of para-
nitrophenylphosphate to para-nitrophenol (Section 3.3.4.6). Para-
nitrophenol was quantified colorimetrically.The relative activities of the
different batches were significantly different (p<0.05).
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3.5 Conclusions
Co-culture of BMP-2 loaded microparticles induced osteogenic differentiation within
a murine osteoblast cell line. This showed that the released BMP-2 was biologically
active and able to induce a biological effect. The publication of these results assisted
our collaborators in gaining ethical approval for an in vivo study.
Relative comparison of three BMP-2 batches identified a less active batch. This batch
was isolated from further study. This defective batch of BMP-2 was still able to induce
differentiation when released from microparticles showing that the controlled release
system was effective even under sub-optimum conditions. The largest batch of BMP-2
(batch 2) exhibited the highest level of biological activity. This batch was set aside for
the large mammal in vivo study.
The variation in these batches was almost certainly due to the lack of quality control
from our supplier. This was a non commercial source of BMP-2 as part of a
collaboration so we had no options for obtaining a commercial batch with full quality
control certification.
3.6 Future Work
The strange pattern of mineral deposition indicated (Figure 3.5) is worthy of further
analysis. It needs to be determined whether this is a result of a BMP-2 concentration
gradient or if themicroparticles have some kind of influence over the pattern ofmineral
deposition.
In order to accurately formulate a clinical growth factor release therapy it will be
essential to determine the concentration of BMP-2 release. A cell line such as C2C12
murine myoblasts that respond proportionally to BMP-2 concentrations could be used.
This chapter confirms that an osteogenic growth factor (BMP-2) can be released and
is biologically active, in addition an active batch of BMP-2 had been selected for the
segmental defect study. Verification of the release of an angiogenic growth factor
will benefit the study. The next chapter addresses this and the application of this
microparticle system in vivo.
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Results III: Preparation for an in
vivo study
4.1 Introduction
The previous two chapters have shown the development of a microparticle system for
the controlled release of growth factors. The release of growth factors over sustained
periods and the biological activity of these released proteins has been shown. The next
step for this technique to become of benefit to humans is preclinical trials. These trials
are carried out in non-human animals. They are required to demonstrate both safety
and efficacy. This chapter details the process of taking experimental material from a
lab and preparing and characterising it in such a way that it can be implanted in vivo.
A large mammal, critically sized, segmental defect model was selected to assess the
effect of multiple growth factor release. Of the large mammal models canine, ovine and
porcine are the most well published. Social pressures have reduced the favorability of
canine models in recent years and although porcine models are very physiologically
comparable to humans, the short length of their tibial long-bones precludes the use of
some implants designed for use in humans.
It has been suggested that a model species should have similar physiological and
pathophysiological conditions to humans in order for the model to be representative.
Humans and sheep have no major difference in bone mineral composition [190] and
sheep metabolic and remodelling rates are similar to that of human bones [191]. Ovine
studies are thought to be goodmodels for human bone turnover and remodelling [192].
Mature sheep have a similar body weight to adult humans and their long bone
dimensions allow the use of human implants [193]. Despite these clear advantaves of
an ovine model there are also disadvantages. Trabecular bone in immature sheep has
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a high collagen content. This means that it has a lower density and stiffness leading
to a higher flexibility that human bone [194]. Secondary osteonal remodelling does
not take place until an average of 7–9 years [193] and mature sheep exhibit a higher
trabecular density and greater bone strength compared to humans [194]. In order to
mitigate these factors, ovine candidates were selected in the age range of 6–7 years. It
is thought that at this age, bone density will be similar to humans and these relatively
old sheep possess the secondary osteon remodelling which is characteristic of human
bone.
Segmental defects are often used to assess bone repair strategies as they show a
quantitative level of new bone generation. This is useful to assess the osteoinductive
and osteoconductive effects of repair strategies. A critically sized osseous defect
should be of dimensions to preclude spontaneous healing [195], this makes it possible
to determine whether a therapeutic approach is significantly effective. The specific
definition of a critically sized defect varies. It has been defined as:
"the smallest size intraosseous wound in a particular bone and species
of animal that will not heal spontaneously during the lifetime of the
animal" [196, 197].
But also as as a defect which shows less than 10 % bony regeneration during the lifetime
of the animal [197]. It is also clear from the literature that theminimum size that renders
a defect ‘critical’ is not well understood. It is unlikely that there will ever be a blanket
definition for a single species since other factors such as defect location, soft tissue or
biomechanical conditions, age, metabolism, systemic conditions, related morbidities,
gender and body weight all play a role in the rate and degree of repair [196, 198].
As a general rule in large mammals, a defect greater than 2–2.5 times the diameter of
the bone has been described as ‘critical’ [198, 199] or in the case of sheep, up to three
times the diameter of the corresponding diaphysis [199].
Our proposed repair strategy combines themicroparticle growth factor delivery system
with a highly porous, structurally supportive scaffold composed of poly ε-caprolactone
and tricalcium phosphate. Poly ε-caprolactone has a very low rate of degradation. A
novel combination of Poly ε-caprolactone and tricalcium phosphate (PCL-TCP) was
first proposed in 2005 [200]. The TCP component has been shown to spontaneously
bond to and integrate with bone as well as provide pH buffering against polymer
degradation [201, 202]. This particular PCL-TCP composite has demonstrated a
homogeneous distribution of TCP and favourable mechanical properties [203]. It has
been suggested that the mechanical properties of porous polymer constructs can be
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improved through the addition of TCP [204].
A fused depositionmodelling (FDM) method of scaffold fabrication can provide repro-
ducible three-dimensional constructs with fully interconnected channel networks [81].
Scaffolds produced in this way from PCL-TCP (80 %-20 %w/w) have demonstrated cell
attachment in vitro [205], osteoprogenitor proliferation and differentiation [205, 206]
and been shown to support bone formation in vivo [200].
The scaffold was designed to fit the proposed defect site. A cylindrical scaffold with
a central void was designed to mimic the tubular structure of a long bone diaphysis.
The scaffold had 70 % porosity and 100 % pore interconnectivity. The pore sizes were
350–500 µm and the polymer strands had a 0/90◦ lay down pattern (Figure 4.1). This
open structure should be favourable for nutrient supply and host tissue ingress.
It is hypothesised that angiogenic factors released fromwithin this scaffold should help
early vascularisation of the defect site. It is hoped that this early angiogenesis will
facilitate the recruitment of progenitor cells and support localised tissue regeneration.
There are concerns that clinical use of BMP-2 can result in bone overgrowth [53]. It
is hoped that a sustained delivery of growth factors will lead to a more physiological
morphology.
4.2 Aims
The aim of this chapter was to develop a formulation and manufacturing method
to fabricate growth factor loaded microparticles. A method was then developed to
combine printed PCL scaffolds with with this growth factor delivery system. This
would enable successful surgical implantation.
This involved fabricating microparticles that would release VEGF and PDGF over a
short time and would release BMP-2 for a longer period. Additionally these growth
factors had to be released at concentrations theorised to elicit a therapeutic response.
Amethodwas devised to combine themicroparticles with the poly ε-caprolactone/tricalcium
phosphate scaffold. This method had to be suitable for use immediately prior to
surgery so that the microparticles could be stored dry and only begin to hydrate after
implantation.
A successful outcome to this chapter will be successful preparation and implantation
of this novel biomaterial.
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4.3 Methods
4.3.1 Determination of a Therapeutic Dose
Before fabricating growth factor loaded microparticles for this study it was important
to estimate the amount of growth factor required to achieve a therapeutic dose. This
was not an easy task as a number of factors can affect the outcome independent of
BMP-2 dose. These include location of administration, condition within the location
and measured outcome. Furthermore, the effect can be species dependent [208].
The majority of published literature regarding the use of BMP-2 and critically sized
osseous defects is for small mammal models and often uses a bolus delivery. Stability
limitations mean that studies using non-sustained, bolus delivery generally use supra-
physiological amounts of BMP-2 just to see an effect.
The lowest dose of BMP-2 that appears to have an effect was utilised in a Rat cranial
defect model [209]. This system delivered 1–2 ng/mm3/day of BMP-2. A VEGF
dose greater that that of a BMP-4 dose can be detrimental to bone development [210].
A VEGF dose slightly lower than that of BMP-2 has been shown to increase bone
formation in a rat cranial model [211]. It was decided, based on this evidence, to aim
for a VEGF dose of 1 ng/mm3/day. Recent studies have shown that equal expression
of PDGF to VEGF has been a suitable level to stabilise the VEGF-induced vasculature
and significantly improve function in a murine ischemic limb muscle model [40].
4.3.2 Fabrication of Growth Factor Loaded Microparticles
Growth factors rhVEGF165 and rhPDGF-BBwere sourced from PEPROTECH (PeproTech
House, London, UK). These particular isomers were selected because of their docu-
mented and effective use in angiogenic and osteogenic regenerative situations [40, 212–
216]. As well as an important role in angiogenesis, PDGF-BB has shown the ability
to induce osteoblast chemotaxis [217]. Batch 2 of BMP-2 was used (Section 3.3.3,
Page 78). Microparticles were fabricated in the larger size range (Section 2.3.3 –
homogenisation protocol) from three different formulations to achieve desired release
profiles for each growth factor. For BMP-2 delivery a slow-releasing formulation of
PLGA 50:50 with 10 %w/w PLGA-PEG-PLGA selected. This would provide a sustained
release for approximately 30 days. Polymer formulations selected for VEGF and PDGF
microparticles were PLGA 85:15 with 30%w/w PLGA-PEG-PLGA and PLGA 50:50 with
20 % w/w PLGA-PEG-PLGA respectively.
Blank microparticles were fabricated to ensure that each defect site would have exactly
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the same mass and combination of polymers. This would ensure that any difference
seen would be due to the effect of growth factors and not scaffold variations.
As before, microparticles contained 1 % w/w protein loading. Protein consisted of a
1:9 ratio of growth factor to HSA. This level of carrier protein exhibited active protein
release is previous studies carried out in Chapter 3. Released BMP-2 with this level
of HSA was able to stimulate the expression of alkaline phosphatase (Section 3.2 on
Page 85).
4.3.3 Fabrication of Coloured Microparticles
Coloured microparticles were fabricated to enhance visibility when they were attached
to the poly ε-caprolactone/tricalcium phosphate scaffold. During microparticle fabri-
cation, 5 mg of the lipophilic dye Oil Red O was added to the organic phase. This was
adequate to colour the microparticles bright red. Microparticles were fabricated as per
the method is Section 2.3.3; homogenisation protocol.
4.3.4 Microparticle Sterilisation
Microparticles were fabricated under clean (but not aseptic) conditions. They were
sterilised using an ultraviolet method (Section 3.3.2). This was deemed the least
detrimental method. Other sterilisation methods such as gamma irradiation are
thought to damage polymers to a greater extent [130]. Previous activity measurements
were carried out on microparticles that had been UV sterilised so this method was
thought to not be significantly detrimental to growth factor activity.
4.3.5 Attaching Microparticles to a Scaffold – DMSO method
An aqueous solution of dimethyl sulphoxide (DMSO) (10 % v/v) was used to soften a
suspension of microparticles. This solution was applied to the scaffold pores and was
drawn in through surface tension. Excess solvent was wicked away and the composite
was gently washed.
4.3.6 Attaching Microparticles to a Scaffold – Fibrin
A procedure was developed whereby a fibrinogen suspension of microparticles could
be injected into the porous scaffold (Figure 4.7). Each end was then clotted using
thrombin. This produced a fibrin plug keeping themicroparticles in the scaffold during
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implantation.
A small polytetrafluoroethylene (PTFE) disk was placed in the bottom of a well in a 24-
well plate. This prevented the fibrin solution sticking. 50 µl of thrombin solution was
added to the well. The microparticles for one tibial defect (2000 mg) were mixed with
1100 µl of fibrinogen solution. This microparticle suspension was added to a modified
5 ml syringe (Figure 4.3). Air bubbles were allowed to escape and the scaffold was
placed on the end of the syringe. This was then inverted and placed into the prepared
well. The microparticle suspension was smoothly injected into the scaffold. Thrombin
solution (30 µl) was added to the top of the scaffold to clot the fibrin. This scaffold was
now ready for implantation.
Fibrinogen Solution Fibrinogen solution (20 mg/ml) was prepared by dissolving
fibrinogen in deionised water at 37 ◦C.
Thrombin Solution Thrombin solution (8 NIHunits/ml) was prepared by dissolving
thrombin in deionised water at 37 ◦C.
Modified Syringe The microparticle suspension behaves like a non-Newtonian fluid.
When shear is applied it resists flow. The suspension could not be extruded form a
standard syringe because as soon as pressure was applied it clogged. This problem
was overcome by truncating a 5 ml syringe at the zero mark. This eliminated bore
narrowing so the microparticle suspension could be ejected from the syringe.
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Figure 4.1: Bioresorbable cylindrical scaffolds made from medical grade poly ε-
caprolactone/tricalcium phosphate 20 % w/w and produced by fused
deposition modelling [207]. Side view (a), top view (b). Outer diameter:
20 mm, height: 300 mm, inner diameter: 8 mm, 70 % porosity, 100 %
pore interconnectivity, 350–500 µm pore size, 0/90◦ lay down pattern. This
scaffoldwas provided by our collaborators Dietmar Hutmacher andMaria
Woodruff (Queensland University of Technology, Brisbane, Australia).
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Figure 4.2: Preparation procedure for incorporating microparticles into the poly ε-
caprolactone/tricalcium phosphate scaffold. Microparticles were sus-
pended in a fibrinogen solution (a) and transferred to a modified syringe
(b).Themodified syringe ismarried to the scaffold (c) and themicroparticle
suspension extruded into the scaffold (d). The ends of the scaffold are
clotted with thrombin solution (e) and the scaffold composite is now ready
to handle/implant (f). This methods is described in Section 4.3.6.
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Figure 4.3: Modified syringe. The end was cut off a 5 ml syringe to eliminate bore
narrowing. This syringe was used to deliver a microparticle suspension
into the porous scaffold. This method was described in Section 4.3.6.
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4.3.7 Imaging microparticles and scaffolds optically
Pilot scaffolds and microparticles were visualised using optical techniques. For low
magnification overviews a digital camera (Sony DSC F717) was used with a macro
setting. For higher magnification images a phase contrast optical microscope was used
(Nikon A1). In order to obtain images with an adequate depth of field, the aperture was
closed down and the light level pushed up.
4.3.8 Micro Computerised Tomography Imaging
Scaffolds were characterised by micro x-ray computed tomography (µCT). Scaffolds
were mounted on a stage at a height of 10 mmwithin the imaging system and scanned.
Measurements were obtained at a voltage of 40 kV, current of 800 µA and voxel
resolution of 20.6 µm. The transmission images were reconstructed using Skyscan
supplied software (NRecon) and quantitative analysis of porosity and pore architecture
was obtained using direct morphometry calculations in the Skyscan CTAn software
package.
Care was taken to define an accurate scaffold boundary to ensure that porosity analysis
did not induce a positive bias by assessing regions outside the scaffold.
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4.4 Results and Discussion
4.4.1 Microparticle Fabrication
Microparticles were fabricated over a two week period. Effort was made to ensure
consistency between batches. Protein release studies were carried out on every batch
that was to be used in vivo and representative batches were sized. Batches containing
BMP-2 were paired up during fabrication and filtered together because each defect
would require two batches, this effectively halved the number of batches requiring
protein release analysis. All others were kept separate.
Release was carried out in triplicate and assessed from 12 batches containing BMP-2, 3
containing VEGF and 3 containing PDGF. No batches appeared anomalous (Figure 4.4).
Microparticles loaded with VEGF and PDGF exhibited less separation than was
anticipated (Figure 4.5, a). The majority of protein release from these formulations
takes place by day 3-4. It can be hypothesised that the release rate in vivowill be slower
than this. Sink conditions were maintained for the in vitro release studies, this will
most likely not be the case in vivo. In addition, growth factors will be released into
the fibrin clot initially so there will be few proteolytic enzymes present to denature the
growth factors. It can be reasonably estimated that these angiogenic factors will be
active within the defect site for up to a week.
When these formulations were being chosen it was thought that thought that temporal
separation between VEGF and PDGF was desirable since PDGF facilitates pericyte
recruitment to stabilise the vascular network induced by VEGF. It was even demon-
strated that VEGF followed by PDGF-BB release was more effective than the growth
factors individually at inducing mature vessel formation and improving function in
a myocardial infarction model [24]. This makes logical sense since one mechanism
follows the other. A more recent publication investigating a murine skeletal muscle
ischemic model showed that early expression of PDGF-BB did not limit VEGF driven
capillary growth and that increased pericyte recruitment in the first four days did not
have a net negative effect on VEGF angiogenesis [40]. This indicates that our delivery
system for VEGF and PDGF should still be highly effective even though we didn’t
achieve the desired VEGF and PDGF temporal separation.
Formulations releasing BMP-2 demonstrated a long duration of release (Figure4.5, b).
The release is less regular than had been seen from this formulation previously (Fig-
ure 2.15, Page 70). This was attributed to PLGA-PEG-PLGA intra-batch variability.
Most of the protein was released at one of two stages. A burst release in the first day
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Figure 4.4: Cumulative protein release from each batch of microparticles to be
used in vivo. Cumulative release of HSA/VEGF (•), HSA/PDGF (N)
and HSA/BMP-2 () from PLGA microparticles. No batches exhibited
anomalous release behaviour. No error bars are shown because this plot
shows individual data points, not averages. All microparticles shownwere
fabricated using the homogenisation method (Section 2.3.3). The PLGA
formulations are described in Section 4.3.2.
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a
b
Figure 4.5: (a) Cumulative release of HSA/VEGF (•) and HSA/PDGF (N) from PLGA
microparticles. These angiogenic factors are delivered over the first few
days. No further release is detected. (b) Cumulative release of HSA/BMP-
2 () from PLGA microparticles. An initial burst release is followed by
sustained release that accelerates at day 21 until day 35.Error bars show
± cumulative standard deviation of the mean; n=9. All microparticles
shown were fabricated using the homogenisation method (Section 2.3.3).
The PLGA formulations are described in Section 4.3.2.
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and a steady release from day 21–35. As with the angiogenic factors, this is unlikely
to be an accurate representation of in vivo release. What is clear is that angiogenic
factors will be released at an early stage and the osteogenic factor will be present at
a later stage. Representative batches of these microparticles were sized using laser
diffraction (Section 2.3.4.2 on Page 41). The size is important because it can affect the
release rate of protein as well as the flow characteristics. It was important that the
microparticles didn’t separate resulting in a non-homogeneous distribution of growth
factors in vivo. The sizes fell within anticipated ranges (Figure 4.6). The formulation
delivering BMP-2 (PLGA 50:50 with 10 % PLGA-PEG-PLGA)were larger than the other
two formulations. This is consistent with previous data indicating that an increasing
PEG concentration leads to smaller microparticles (Figure 2.4, Page 49).
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Figure 4.6: Size distributions of representative batches of microparticles from each
formulation. PLGA 85:15 with 30% PLGA-PEG-PLGA (HSA/VEGF) (•),
PLGA 50:50 with 20% PLGA-PEG-PLGA (HSA/PDGF) (N) and PLGA
50:50 with 10% PLGA-PEG-PLGA) (HSA/BMP-2) () (Section 4.3.2) using
the homogenisation method (Section 2.3.3.2). Microparticles were sized
using laser diffraction (Method 2.3.4.2). The size distributions fell within
the anticipated ranges shown in Chapter 2.
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4.4.2 Preparation of the Scaffold/Microparticle Composite
It was important to combine the microparticles with the scaffold in such a way that
they would remain in place after implantation and during protein release. There were
two ways to approach this:
1. Utilising intrinsic properties of the PLGA to adhere the microparticles to the
scaffold structure. Microparticles become ‘sticky’ when exposed to heat or
solvent. They could then be affixed to the scaffold and solidified by either cooling
or allowing the solvent to evaporate.
2. The use of extrinsic components to affix the microparticles to the scaffold.
Hydrogels were a likely candidate. Glues and chemical cross-linkers were
considered as well.
Method 1 was explored by affixing coloured microparticles (Section 4.3.3, Page 100) to
small PCL-TCP scaffolds using DMSO as a solvent (Section 4.3.5, Page 100).
Thismethod (after some optimisation) gave gooddistribution ofmicroparticles through-
out the small test scaffolds (Figure 4.7 a & b). At higher magnifications is was apparent
that the microparticles were deformed by the process and aggregated together (Fig-
ure 4.7 c & d). There were concerns that this would affect protein release. This method
was also only suitable for the smaller test scaffolds. For larger scaffolds it was difficult
to get the microparticles into deep pores.
Method 2 was selected for use in the large mammal study as it was thought to pose
the least risk of particle damage. A fibrin clot was selected at the suggestion of our
collaborators who were carrying out the in vivo work. They had used it for other
osteochondral applications successfully. The fibrinogen would clot and immobilise the
microparticles during implantation then become enzymatically degraded in vivo. This
fibrin clot mimics conditions that would result normally. The defect site would bleed,
this would penetrate into the scaffold and form a natural clot.
A full-scale PCL-TCP scaffold was obtained from our collaborators for microparticle
attachment studies. Microparticles were immobilised within the scaffold and held in
place with a fibrin clot (Section 4.3.6, Page 100). Different combinations of fibrinogen
concentration and volume were assessed because the final microparticle suspension
had to adhere to two key requirements.
1. The total volume of the microparticles in suspension had to be less than or equal
to the available space within the scaffold.
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Figure 4.7: Images of microparticles attached to small poly ε-caprolactone/tricalcium
phosphate test scaffolds. Microparticles were dyed red to enhance
contrast to the scaffold (Section 4.3.3). Microparticles were attached
to the scaffold using a DMSO solvent softening method (Section 4.3.5).
Homogeneous attachment can be seen at low magnification (a,b) but
at higher magnification microparticles have aggregated and deformed
as a result of the solvent treatment (c,d). Scaffolds were imaged
using a commercial digital camera and optical microscopy techniques
(Section 4.3.7).
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2. The viscosity of the microparticle suspension had to allow it to flow into the
scaffold and keep it within the scaffold after each end was clotted with thrombin.
The final protocol facilitated these needs. The scaffold with the particles within it
(Figure 4.8) could be immediately handled after clotting with thrombin.
The prepared scaffold was assessed using micro computerised x-ray tomography
(µ-CT) to investigate the distribution of microparticles within the scaffold. An
even distribution was preferable to allow an even diffusion of growth factors after
implantation. It can be seen from a longitudinal x-ray image (Figure 4.9, a) and a
computer generated transverse ‘slice’ (Figure 4.9, b) that the microparticles are mainly
confined to the central section of the scaffold. This leaves a porous outer structure
available for tissue ingress and remodelling. This porous structure can be easily seen
in the three-dimensional computer-generated tomographic images (Figure 4.10).
Once the microparticles degrade, the central section would once again become empty.
This would more accurately mimic physiological bone structure.
The porosity of the whole scaffold, once filled with microparticles, was 53 % and
the microporosity within the central microparticle filled section was 11 %. The voxel
resolution was 20.6 µm so porosity below this size could not be resolved. There would
most likely be a degree of microporosity. This would facilitate the diffusion of released
bioactive molecules.
A high degree of porosity is required for effective tissue ingress [73]. The open outer
structure of this scaffold meets these requirements.
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Figure 4.8: Image of poly ε-caprolactone/tricalcium phosphate scaffold after mi-
croparticles had been added. The central void contains the majority of the
microparticles. The pores appear to also contain microparticles. Micro-CT
analysis later revealed that the microparticles are only in the periphery of
the pores. The open porous structure remains within. This scaffold was
imaged using a commercial digital camera described in Section 4.3.7.
Figure 4.9: Images of the poly ε-caprolactone/tricalcium phosphate scaffold and mi-
croparticle composite obtained using X-rays and computer reconstruction
(Section 4.3.8). Microparticles can be seen in the periphery of the pores at
top top of the scaffold (a). Microparticles mainly inhabit the central section
of the scaffold. A medial slice (reconstructed from multiple lateral X-rays)
confirms that the microparticles contained within the central section of the
scaffold. The outer pores are available for tissue ingress.
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Figure 4.10: Three dimensional reconstructed images of the poly ε-
caprolactone/tricalcium phosphate scaffold and microparticle
composites (Section 4.3.8). These images compliment initial X-
ray images. The outer structure is available for tissue ingress and
physiologically matches the shape of a bone collar.
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4.5 Conclusions
The goals of this work were achieved. Populations of microparticles were fabricated
with the growth factors VEGF, PDGF and BMP-2 encapsulated within them. Protein
release rate was assessed from each batch of microparticles. Each batch was found
to meet the hypothesised requirements. Angiogenic factors (VEGF and PDGF) were
delivered initially with the aim of defect vascularisation. Over a more sustained
duration and at a later time point, BMP-2 was delivered.
Actual protein release data was used to prepare therapeutic doses of the microparticle
combinations for use in vivo. A method was devised to combine these microparticle
populations with the structurally supportive scaffold in theatre immediately prior to
implantation. This combination of microparticles and scaffold was assessed to ensure
the porous structure of the scaffold still remained.
Implantation of the biomaterial was successfully carried out in a critically sized defect
model.
The mass of microparticles implanted in vivo was calculated from available data as a
best guess in order to achieve therapeutic loadings within the defect site (Section 4.3.1).
Most of the quantitative data regarding the delivery of growth factors utilises a non-
controlled release method of deliverymaking it very difficult to extrapolatemeaningful
data for a controlled release formulation. For this study assumptions were made and
the levels of growth factor were administered at the top end of estimated therapeutic
levels. The high volume of microparticles compromised the hollow nature of the
scaffold but still left the channels within the wall clear. Ideally a lower overall volume
of microparticles would have been delivered in order to maximise porosity. To achieve
this in future either a more concentrated formulation of growth factor within the
miroparticles would be used or a lower dose of growth factor will be used.
4.6 Future Work
The synergistic nature of VEGF, PDGF and BMP-2 has been previously shown in
various combinations but rarely under controlled delivery or at specific temporal
intervals. We hope to highlight the importance of temporal delivery of these growth
factors. If we can express these growth factors in vivo at times conducive with the
physiological healing process and at physiological concentrations we hope to achieve a
better clinical outcome. Not just a faster healing time but a better final tissue structure.
With the aid of additional funding, further in vivo assessment could take place to
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identify optimum combinations and concentrations of these growth factors.
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Final Conclusions and Future Work
5.1 Discoveries made
The scope of this research was to carry out the groundwork necessary so that the
controlled release of growth factors (GFs) could be assessed in vivo in future studies.
This research was approached in a very stepwise and pragmatic way. The discoveries
made here are an essential step towards future clinical therapies.
The objective of this study was to develop a controlled delivery system for growth
factors with tunable release kinetics. The strategy was to include a hydrophilic
polymer within the PLGA microparticles in order to modulate water ingress, affecting
protein diffusion and polymer degradation. This thesis demonstrates for the first time
that protein release kinetics can be altered from PLGA using the triblock copolymer
PLGA-PEG-PLGA. This novel delivery system was able to deliver different growth
factors with independent release kinetics. These kinetics could be tailored to the
physiological expression of these growth factors in order to assess the next generation
of GF therapies.
This microparticle delivery system was able to provide GF release kinetics decoupled
from polymer degradation. A quasi zero order release profile was achieved using 10
% w/w PLGA-PEG-PLGA with 50:50 PLGA. Other formulations were able to deliver
shorter release durations. Three of these formulations were selected as promising
candidates from clinical growth factor delivery.
The structure of proteins released from polyesters will always be difficult to maintain
and this loss of structure leads to protein denaturation. Using a surfactant copolymer,
a chaperone protein (HSA) and carefully refined fabrication and processing protocol,
issues of denaturation were mitigated. I demonstrated the release of active lysozyme
and verified the release of active BMP-2 using a pre-osteoblast cellular assay.
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Furthermore, a method was demonstrated whereby this microparticle controlled
delivery system could be combined with a scaffold offering structural support. This
would theoretically help to localise any physiological effect to a desired location as
well as offering structural support. The growth factors explored were selected with
bone regeneration as a focus so mechanical stability is an essential aspect.
5.2 Lessons learned
The current state of growth factor controlled delivery research is disjointed. even
similar delivery systems vary between research groups as the fabrication protocols
inevitably vary. A number of studies have assessed different growth factors from
different formulations using in vitro and in vivo models. This makes if very difficult to
draw sweeping conclusions regarding optimum systems or dosages or combinations
of growth factors. The main limiting factor prohibiting larger growth factor studies is
the high cost. Both he high cost of recombinant growth factors, but also the man-hours
required to carry out lengthy studies and assess the results effectively.
One essential method to mitigate costs is the use of model proteins for initial ex-
ploratory studies. This thesis effectively verifies lysozyme as an effective model for
BMP-2. Selection of suitable model proteins can be difficult. the physicochemical
characteristics of the molecule must be similar to the growth factor of interest but
the model protein must also be low-cost and have simple and effective methods to
determine structural changes such as an enzymatic assay.
5.3 Future work
The expression of different growth factors at different stages of fracture repair can be
measured and it is often assumed that these are the correct levels and combinations
required for effective healing. This needs further exploration and validation. Until
this takes place, the administration of growth factors for therapeutic purposes is guess
work. This microparticle system provides a tool for the exploration of growth factors
and will imminently lead to a large mammal preclinical model. I feel that there is
scope to justify a number of smaller animal models simply assessing a variety of release
rates of different growth factors. Something simple such as a Murine subcutaneous
implantation would provide information very useful for furthering the development
of growth factor therapies. Factors such as an effective therapeutic dose of growth
factors still needs to be determined.
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The difficulties in achieving effective and validated controlled release in vitro are
extreme. I strongly believe that money and time would be far more productively spent
if in vivomodels are used at a far earlier stage to assess biological effects. The pathway
through in vitro studies should be laid out prior to studies commencing and required
outcomes determined so that this stage is not all consuming. It is far too easy to try and
analyse too many variables when their impact on clinical outcomes may be minimal.
The triblock copolymer, PLGA-PEG-PLGA, has proven effective in modulating the
release of protein from polyesters. Further exploration of different molecular weights
of PLGA-PEG-PLGA was beyond the scope of this thesis but may provide a plethora
of additional protein release profiles. Even simple aspects such as the hydrolytic
degradation of the polymers over time (in storage) should be addressed if this is
ever to become a clinical therapy. This thesis looked at this superficially with
GPC measurements at different time points but more sampling, to assess intra-batch
variation, as well as accelerated degradation studies would reveal essential polymer
stability information.
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Chemicals & Reagents
Table A.1: Chemicals and reagents..
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Instruments and Apparatus
Table B.1: Instruments and apparatus.
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Protein Release Comparison
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APPENDIX C: PROTEIN RELEASE COMPARISON
Figure C.1: Comparison of protein release from microparticles in the 22–26 µm (N)
and 70-100 µm (•) size ranges formulated form PLGA 50:50 (10 % w/w
PLGA-PEG-PLGA). Both microparticle batches contain BMP-2 and HSA
(1:9) loaded into the microparticles at 1 % w/w. Total protein release was
assessed. The release of protein from 22–26 µm (N) microparticles was
carried out by Helen Cox. The different microparticles release protein for
a similar length of time although a greater burst release if seen from the
smaller microparticles. Error bars show ± cumulative standard deviation
of the mean; n=3.
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Agarose-gelatin Conjugate
D.1 Agarose-gelatin Conjugate Fabrication
A conjugate of agarose and gelatin was fabricated utilising a 1,1-carbonyldiimidazole
(CDI) crosslinker (Figure E.1).A protocolwas developed based on a publishedmethod [218].
Low melting point agarose (A2576, Sigma Aldrich) (0.2 g) was dissolved in DMSO (5
ml), this was combinedwith 2ml of DMSO containing CDI crosslinker (115533, Aldrich)
(1.3 or 32.7 mM). This caused the CDI to activate the agarose hydroxyl groups. Gelatin
(G1890, Sigma) (0.2 g) in 3 ml DMSO was added and the reaction allowed to proceed
for 12 hours at room temperature. The conjugate was then dialysed against deionised
water to remove the DMSO. The resultant hydrogel was washed with bicarbonate
buffer (0.1 M, pH 8.5). This removed remaining imidazolyl carbamate. The hydrogel
was washed finally with more deionised water then lyophilised for storage.
The hydrogel was prepared for use by dissolving the agarose-gelatin in phosphate
buffered saline to produce a 1 % w/v solution. This was carried out at 80 ◦C. This
solution was pipetted into a 6-well plate (500 µl/well) or a 96-well plate (37 µl/well).
There was a 10 minute window before gelation took place at room temperature, this is
when microparticles could be added. The gel was sterilised under ultraviolet light for
20 minutes.
Protein assays were ineffective at assessing gelatin incorporation due to interference
from the agarose. Gelatin incorporation was assessed based on yields. The assumption
was made that 100 % agarose recovery occurred and any mass increase was due to
gelatin.
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Figure D.1: Schematic showing the covalent coupling of gelatin to agarose through
the activation of agarose hydroxyl groups with CDI.
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D.2 Cell Quantification
The number of metabolically active cells was determined using the CellTiter 96 R© kit
(Promega). This kit utilises a novel MTS1 reagent that is reduced by dehydrogenase
enzymes (found in metabolically active cells). This forms (in the presence of phenazine
methosulfate, PMS) a soluble formazan product that can be photometrically quantified.
The MTS kit was selected in preference to the more traditional MTT assay due to ease
of use and also the flexibility. If necessary cell culture plates can be further incubated
after photometric measurement and the cells remain metabolically active (unlike the
MTT assay).
Reconstituted MTS working reagent (20 µl) was added to each well of a 96-well tissue
culture plate containing cells and culture media (100 µl). This plate was then incubated
in a cell culture incubator for the appropriate period of time and read photometrically
at 490 nm.
Different cell types metabolise MTS at different rates so to ensure suitable resolution
and accuracy of data is was essential to assess the response ofMC3T3-E1 cells at known
densities for different incubation periods. These results favoured a long incubation
period of 260 minutes (Figure D.2).
13-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
127
APPENDIX D: AGAROSE-GELATIN CONJUGATE
Figure D.2: Calibration plot to ascertain how long to incubate MC3T3-E1 cells
with MTS working reagent. Working reagent as incubated for 80
minutes (◦), 140 minutes (•), 200 minutes () and 260 minutes ().
The longest incubation (260 minutes ) gave the greatest difference in
absorbency in response to different cell densities with no indication of a
saturation plateau. This time period was selected for further quantitative
assessments.
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D.3 Conjugate Biocompatibility
An agarose-gelatin conjugate was fabricated using two different cross-linker concen-
trations (1.3 and 32.7 mM) to produce a different amount of gelatin incorporation.
Gelatin incorporation was found to be 12 % and 28 % respectively. This was close
to the published values.
The gelation of these gels was assessed and the characteristics were found to be similar
to those of non-functionalised agarose. The gels were suitable for micro-injection of
microparticles.
Cell compatibility and proliferation was assessed on these agarose-gelatin hydrogels.
Suitable control groups were selected. Experimental groups are detailed (Table D.1).
Numerical Identification Description
1 Cell culture treated tissue culture plastic
2 Non treated tissue culture plastic
3 Agarose hydrogel
4 Physical mixture of agarose and gelatin (50:50)
5 Physical mixture of agarose and gelatin (80:20)
6 Agarose-gelatin conjugate (88:12)
7 Agarose-gelatin conjugate (72:28)
Table D.1: Experimental groups to assess the biocompatibility of various hydrogels
with MC3T3-E1 cells.
The aim was to compare the biocompatibility of of the agarose-gelatin conjugate versus
a physical mixture of agarose and gelatin. In addition this experimentwould determine
whether the different levels of gelatin incorporation affect cell proliferation/metabolic
activity.
Cells were cultured on different substrates (Table D.1) and imaged after 48 hours in
culture (Figure D.3). On tissue culture plastic (Figure D.3, Row 1) the cells are difficult
to see because they become flat on the favourable surface. In contrast, non tissue
culture treated plastic causes the cells to be more visible (Figure D.3, Row 2). Agarose
hydrogel or physical mixtures of agarose and gelatin were highly unfavourable to cell
attachment (Figure D.3, Rows 3–5). This highlights the initial problem. These gels have
excellent gelation and physical characteristics meaning that they are good substrates
for the positioning of microparticles but they are incompatible with mammalian cell
culture.
Cell attachment and branching was exhibited by cells cultured on the agarose-gelatin
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conjugate with the higher amount of gelatin incorporation (Figure D.3 Row 7). This
indicates that this gel is both compatible with micro-injection and cell attachment.
Metabolic activity of these cultures was assessed at 72 hours using an MTS assay to
determine the effect of the gels on proliferation and metabolic activity of MC3T3-E1
cells (Figure D.4). Cells cultured on tissue culture treated and non-tissue culture treated
plastic (Groups 1 & 2) exhibited the greatest metabolic activity and optical microscopy
confirmed a high number of cells. Cells cultured on agarose and agarose mixed with
gelatin (Groups 3–5) showed very little difference to the expected metabolic activity
upon seeding. The same was true for agarose cross-linked with only 12 % gelatin
(Group 6). Agarose cross-linked with 28 % gelatin (Group 7) showed significantly
higher (p<0.005) metabolic activity than all other gels assessed. This indicated that cells
were proliferating and metabolically active. Optical microscopy images confirmed an
increase in cell number.
This indicated that agarose cross-linked with 28 % gelatin is a potential candidate as a
cyto-compatible substrate for microparticle patterning and diffusion studies.
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Figure D.3: Phase contrast optical microscopy images of MC3T3-E1 cells cultured
on different substrates for 48 hours. Columns (a, b & c) show replicate
images of representative sections, rows (1–7) correspond to experimental
conditions (Table D.1, Page 129). The conjugate with a higher level of
gelatin incorporation (Row 7) indicates cell anchorage and spreading.
In contrast, agarose alone or physical mixtures of agarose and gelatin
(Rows 3–5) show poor cell attachment and in the case of agarose (Row 3)
the cells begin to aggregate.
131
APPENDIX D: AGAROSE-GELATIN CONJUGATE
Figure D.4: Cell number assessed using a metabolic activity assay. MC3T3-E1 cells
were cultured on different substrates (Table D.1) and assessed after 3 days
in culture. The dashed line indicates the seeding density of cells. Activity
was normalised to cell number based on initial calibration studies.
Agarose crosslinked with 28 % gelatin (Group 7) appears significantly
more favourable to cellular proliferation than physical mixtures of the gels
although not at favourable as tissue culture plastics.
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APPENDIX E
Para-nitrophenol Calibration
Figure E.1: Known concentrations of para-nitrophenol (CAS: 100-02-7, Sigma) were
assessed photometrically to produce this calibration plot. The equation of
this trend-line (least squares) was then used to convert absorbance values
into concentrations of para-nitrophenol.
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Comparison p-value
Day 10
1.mp.low - 2.mp.high 0.00000000002142
1.mp.low - 3.mp.osteogenic 0.5787
1.mp.low - 4.control 0.01081
2.mp.high - 3.osteogenic 0.0000000000000002283
2.mp.high - 4.control 0.0000000000000002200
3.osteogenic - 4.control 0.0009948
Day 17
1.mp.low - 2.mp.high 0.001205
1.mp.low - 3.mp.osteogenic 0.001684
1.mp.low - 4.control 0.01997
2.mp.high - 3.osteogenic 0.1499
2.mp.high - 4.control 0.00003789
3.osteogenic - 4.control 0.00001391
Day 24
1.mp.low - 2.mp.high 0.01273
1.mp.low - 3.mp.osteogenic 0.00007766
1.mp.low - 4.control 0.8840
2.mp.high - 3.osteogenic 0.4417
2.mp.high - 4.control 0.01787
3.osteogenic - 4.control 0.007858
Table F.1: Statistical significance values from a Welch t-test comparing alkaline phos-
phatase expression fromMC3T3 cells subjected to different environments at
three time points. This data was discussed in section 3.4.2 on page 84.
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